Heterocyclic compound as alpha5-GABAA receptor modulator
By developing heterocyclic compounds with α5-GABAA receptor inhibitory activity, the non-specific binding problem of α5-GABAA receptor modulators in the prior art was solved, and the selective regulation of α5-GABAA receptor was achieved, which significantly improved the Treatment effect and safety, suitable for the treatment of various cognitive diseases.
Patent Information
- Application Number
- CN202410656858.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-05-17
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
Existing α5-GABAA receptor modulators nonspecifically bind to multiple subunits of GABAA receptors, resulting in adverse reactions such as drug tolerance, sedation, anxiety or convulsions, and it is difficult to selectively and specifically regulate α5-GABAA receptors. , affects the treatment effect.
A new class of heterocyclic compounds with inhibitory activity of α5-GABAA receptors is developed for the preparation of drugs for the treatment, prevention or improvement of diseases associated with α5-GABAA receptors, through specific structural design and Synthesis method provides selective regulation of α5-GABAA receptor.
It has achieved significant regulatory effects on the α5-GABAA receptor, exhibited excellent pharmacokinetic properties and high safety, and has high drug properties, which can effectively treat diseases mediated by the α5-GABAA receptor, such as Al Zheimer's disease, memory disorders, etc.
Smart Images

Figure CN119019425A_ABST
Abstract
Description
[0001] The present invention claims:
[0002] The patent application number is 202310611467.9 and the name is “An α5-GABA A The priority of the prior application for "receptor modulators and uses thereof";
[0003] The patent application number is 202311371052.5 and the name is "An α5-GABA A The priority of the prior application for "receptor modulators and uses thereof";
[0004] The patent application number is 202410070306.8 and the name is "An α5-GABA A The priority of the prior application for "receptor modulators and uses thereof";
[0005] Priority to the prior application for patent application number 202410624357.0, entitled “A heterocyclic compound as an α5-GABAA receptor modulator”, filed with the State Intellectual Property Office of China on May 17, 2024;
[0006] The entirety of said prior application is incorporated herein by reference. Technical Field
[0007] The present invention belongs to the field of medicine, and in particular, the present invention relates to a kind of α5-GABA A Heterocyclic compounds that are receptor modulators. Background Art
[0008] GABA A GABA receptors are associated with a variety of diseases and are possible therapeutic targets, which has also promoted the A Research on the physiological and pharmacological effects of different receptor subunits. For example, studies using genetically modified mice have shown that the most widely distributed α5 subunit of the γ-aminobutyric acid A receptor (α5-GABA A Benzodiazepine receptors α2-GABA is the main target of benzodiazepines (BDZ) drugs for sedation and amnesia. A Receptors and α3-GABA A The receptors are associated with the anticonvulsant and antianxiety effects of drugs. AThe receptor is an inhibitory receptor in the central nervous system of mammals, mainly distributed in the hippocampus of the brain. It has an inhibitory effect on hippocampal neurons by regulating the outward current of chloride ions. Its expression level in the cerebral cortex is very low and is almost not expressed in other brain regions. The hippocampus is the main site for cognitive functions such as learning and memory, which indicates that α5-GABA A Receptors may be related to cognitive functions such as learning and memory. In addition to BDZ drugs, there are many other drugs such as propofol, etomidate, barbiturates and neurosteroids that can stimulate GABA A The allosteric regulatory sites of the receptors enhance the neural function of GABA, thereby producing corresponding pharmacological effects, which play an anesthetic, antianxiety, sedative or anti-epileptic role in clinical practice. A The non-specific binding of multiple subunits of the receptor leads to many adverse reactions such as drug tolerance, sedation, anxiety or convulsions. Therefore, researchers have been committed to studying and discovering the specific binding of a GABA receptor. A Drugs that have selective and specific effects on receptor subunits.
[0009] Numerous studies have shown that α5-GABA A Changes in receptor excitability can affect cognitive functions such as learning and memory, leading to the occurrence of some diseases such as postoperative cognitive dysfunction, pain, depression, schizophrenia and Down syndrome, etc. Allosteric modulators can treat or improve these diseases.
[0010] Considering α5-GABA A Many pharmaceutical companies, including Roche, are engaged in the study of the specific distribution and function of α5-GABA receptors in the hippocampus of the brain. A A large number of compounds have been synthesized in the study of receptor ligands, especially those targeting α5-GABA in the hippocampus of the brain. A α5-GABA receptor inverse agonists, of which α5IA and MRK-016 have shown good effects in treating cognitive diseases in animal disease models and human trials, especially in treating Alzheimer's disease. A Receptor inverse agonists can be used to treat cognitive diseases, especially Alzheimer's disease. Patent application US20110224278A1 discloses a novel α5-GABA A Inverse agonists of the receptors may be used to treat multi-infarct dementia and stroke-related disorders. Summary of the invention
[0011] The purpose of the present invention is to provide a new class of compounds having α5-GABA A The modulatory activity of receptors, in particular, with α5-GABA ATo this end, the present invention also provides these compounds and pharmaceutically acceptable salts thereof for use in the preparation and manufacture of drugs for treating, preventing, or improving diseases related to α5-GABA A The invention also provides a method for preparing a compound of formula I, and an intermediate useful in such a method.
[0012] In a first aspect of the present invention, there is provided a compound of formula IA, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof:
[0013]
[0014] in,
[0015] X 1 N or CR 5 ;
[0016] Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring;
[0017] R 1 Selected from halogen, deuterium, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;
[0018] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0019] p is selected from 0, 1, 2, 3, 4 or 5;
[0020] R 2 Selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl;
[0021] The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0022] m is selected from 0, 1 or 2;
[0023] Or, R 2 and R 2 The carbon atom to which it is attached forms a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0024] L 1 and L 2 Each independently does not exist, or is selected from R a The replaced C 1-6 Alkylene;
[0025] Z is selected from NR b , O or S;
[0026] Ring B is selected from a 5-10 membered heteroaromatic ring;
[0027] R 3 Selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;
[0028] The R 3 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo (=O), hydroxy, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 Alkyl-substituted 5-10 membered heteroaryl, -(C=O)NR 7 R 8, C substituted with 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO 2 -C 1-6 alkyl;
[0029] R 4 is selected from halogen, oxo (=O), hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0030] The R 4 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0031] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
[0032] R 5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0033] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0034] R 7 and R 8 are independently H or C 1-6 Alkyl, or R 7 and R 8 Together with the nitrogen atom connected thereto, it forms a 5- or 6-membered heterocycloalkyl group, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3;
[0035] R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;
[0036] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
[0037] In the first aspect of the present invention, there is provided a compound of formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof:
[0038]
[0039] in,
[0040] X 1 N or CR 5 ;
[0041] Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring;
[0042] R 1 Selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7Cycloalkyl;
[0043] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0044] p is selected from 0, 1, 2, 3, 4 or 5;
[0045] R 2 , R 6 are independently selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl;
[0046] The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0047] Or, R 2 and R 6 The carbon atom to which it is attached forms a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0048] L 1 and L 2 Each independently does not exist, or is selected from R a The replaced C 1-6 Alkylene;
[0049] Z is selected from NR b , O or S;
[0050] Ring B is selected from a 5-10 membered heteroaromatic ring;
[0051] When L 1Does not exist, L 2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R 2 Not tert-butyl,
[0052] R 3 Selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;
[0053] The R 3 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo (=O), hydroxy, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 Alkyl-substituted 5-10 membered heteroaryl, -(C=O)NR 7 R 8 , C substituted with 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO 2 -C 1-6 alkyl;
[0054] When L 1 Does not exist, L 2 is methylene, X 1 N, R 2 Methoxy, group for When R 3 Selected from
[0055] When L 1 Does not exist, Z is O, L 2 is methylene, X 1 N, R 2 is methoxy, R 6 is hydrogen, group for When R 3 Selected from
[0056] When L 1 Does not exist, Z is O, L 2 is methylene, X 1 N, R 2 is methoxy, R 6 is methyl or methoxy, the group for When R 3 Selected from
[0057] R 4 Selected from deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0058] The R 4 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0059] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
[0060] R 5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0061] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0062] R 7 and R 8 are independently H or C 1-6 Alkyl, or R 7 and R 8 Together with the nitrogen atom connected thereto, it forms a 5- or 6-membered heterocycloalkyl group, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3;
[0063] R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;
[0064] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
[0065] In a preferred embodiment of the present invention, the compound represented by formula IA, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, is characterized in that the compound is selected from the following structures:
[0066]
[0067] in,
[0068] X 1 N or CR 5 ;
[0069] Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring;
[0070] R 1 Selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;
[0071] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0072] p is selected from 0, 1, 2, 3, 4 or 5;
[0073] R 2 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl;
[0074] The R 2 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0075] m is selected from 0, 1 or 2;
[0076] L 1 and L 2 Each independently does not exist, or is selected from R a The replaced C 1-6 Alkylene;
[0077] Z is selected from NR b , O or S;
[0078] Ring B is selected from a 5-10 membered heteroaromatic ring;
[0079] R 3 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;
[0080] The R 3Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 Alkyl-substituted 5-10 membered heteroaryl, -(C=O)NR 7 R 8 , C substituted with 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO 2 -C 1-6 alkyl;
[0081] R 4 Selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0082] The R 4 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0083] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
[0084] R 5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0085] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0086] R 7 and R 8 are independently H or C 1-6 Alkyl, or R 7 and R 8Together with the nitrogen atom connected thereto, it forms a 5- or 6-membered heterocycloalkyl group, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3;
[0087] R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;
[0088] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
[0089] In a preferred embodiment of the present invention, the compound represented by formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, is characterized in that the compound is selected from the following structures:
[0090]
[0091] in,
[0092] X 1 N or CR 5 ;
[0093] Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring;
[0094] R 1 Selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;
[0095] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0096] p is selected from 0, 1, 2, 3, 4 or 5;
[0097] R 2 , R 6 Each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl;
[0098] The R 2 , R 6 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0099] L 1 and L 2 Each independently does not exist, or is selected from R a The replaced C 1-6 Alkylene;
[0100] Z is selected from NR b , O or S;
[0101] Ring B is selected from a 5-10 membered heteroaromatic ring;
[0102] When L 1 Does not exist, L 2is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R 2 Not tert-butyl,
[0103] R 3 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;
[0104] The R 3 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 Alkyl-substituted 5-10 membered heteroaryl, -(C=O)NR 7 R 8 , C substituted with 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO 2 -C 1-6 alkyl;
[0105] When L 1 Does not exist, L 2 is methylene, X 1 N, R 2 Methoxy, group for When R 3 Selected from
[0106] R 4 Selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0107] The R 4Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0108] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
[0109] R 5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0110] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0111] R 7 and R 8 are independently H or C 1-6 Alkyl, or R 7 and R 8 Together with the nitrogen atom connected thereto, it forms a 5- or 6-membered heterocycloalkyl group, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3;
[0112] R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;
[0113] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2 -C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
[0114] In a preferred embodiment of the present invention, the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms.
[0115] In a preferred embodiment of the present invention, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;
[0116] In a preferred embodiment of the present invention, ring A is selected from benzene ring, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine;
[0117] In a preferred embodiment of the present invention, ring A is selected from a benzene ring, isoxazole or oxadiazole.
[0118] In a preferred embodiment of the present invention, ring A is selected from
[0119] In a preferred embodiment of the present invention, R 1 Selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;
[0120] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.
[0121] In a preferred embodiment of the present invention, R 1Selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen.
[0122] In a preferred embodiment of the present invention, R 1 Selected from deuterium (D), F, Cl, methyl, methoxy, -CHF 2 , -CF 3 、-CD 3 , cyclopropyl.
[0123] In a preferred embodiment of the present invention, Selected from
[0124] In a preferred embodiment of the present invention, Selected from
[0125] In a preferred embodiment of the present invention, the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2, or 3 heteroatoms;
[0126] p is 0, 1, 2, 3, 4 or 5;
[0127] R 1 Selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, C 3-7 Halogenated cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy; when there are multiple substituents, the substituents are the same or different;
[0128] Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;
[0129] Preferably, ring A is selected from benzene ring, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine;
[0130] More preferably, ring A is selected from a benzene ring, isoxazole or oxadiazole.
[0131] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0132]
[0133] Among them, X2 N or CR 5 ;
[0134] R 5 Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0135] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0136] X 1 , Ring B, R 1 , R 2 , R 3 , R 4 , R 6 ,p,n,L 1 and L 2 is as defined in the first aspect of the present invention.
[0137] In a preferred embodiment of the present invention, R 5 Selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen.
[0138] In a preferred embodiment of the present invention, R 5 Selected from deuterium (D), F, Cl, methyl, methoxy, -CHF 2 , -CF 3 、-CD 3 , cyclopropyl.
[0139] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0140]
[0141] Among them, X 2 N or CR 5 ;
[0142] R 5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C3-7 Cycloalkyl;
[0143] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0144] X 1 , Ring B, R 1 , R 2 , R 3 , R 4 , p, m and n are as defined in the first aspect of the present invention;
[0145] L 1 and L 2 is as defined in the first aspect of the present invention.
[0146] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0147]
[0148] Among them, R 5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;
[0149] The R 5 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0150] Ring B, R 1 , R 2 , R 3 , R 4 , R 6 , n, L 1 and L 2 is as defined in the first aspect of the present invention.
[0151] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0152]
[0153]
[0154] Among them, ring B, R 1, R 2 , R 3 , R 4 , m and n are as defined in the first aspect of the present invention;
[0155] L 1 and L 2 is as defined in the first aspect of the present invention.
[0156] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0157]
[0158] Among them, ring B, R 1 , R 2 , R 3 , R 4 , L 2 and n are as defined in the first aspect of the present invention;
[0159] When L 2 Selected from methylene, R 2 Selected from methoxy, R 1 When selected from methyl, R 3 Selected from
[0160] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0161]
[0162] Among them, ring B, R 1 , R 2 , R 3 , R 4 , L 2 and n are as defined in the first aspect of the present invention;
[0163] When L 2 Selected from methylene, R 2 Selected from C 1-6 Alkoxy, R 1 Selected from halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy (C 1-6 ) alkyl, C 3-7 Cycloalkyl (C 1-6 ) alkoxy, C 3-7 Cycloalkyl (C 1-6 ) alkoxy (C 1-6 ) alkyl, R 3 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7Cycloalkenyl, C 4-10 When R 3 Substituted with 1, 2, 3 or 4 substituents selected from the group consisting of oxo.
[0164] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0165]
[0166] Among them, ring B, R 1 , R 2 , R 3 , R 4 , L 2 and n are as defined in the first aspect of the present invention;
[0167] When L 2 is selected from methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R 2 Not tert-butyl,
[0168] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0169]
[0170] Wherein, ring D is a 5-8 membered heterocyclic ring containing at least one O atom;
[0171] Ring B, R 1 , R 2 , R 3 , R 4 , R 6 , L 1 , L 2 and n are as defined in the first aspect of the present invention.
[0172] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0173]
[0174] Wherein, ring D is a 5-8 membered heterocyclic ring containing at least one O atom;
[0175] Ring B, R 1 , R 2 , R 3 , R 4 , L 1 , L 2 and n are as defined in the first aspect of the present invention.
[0176] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0177]
[0178] Among them, R 2 , R 6 Not at the same time hydrogen;
[0179] Ring B, R 1 , R 2 , R 3 , R 4 , R 6 , L 1 , L 2 and n are as defined in the first aspect of the present invention.
[0180] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0181]
[0182] Among them, R 2 , R 6 is hydrogen; Selected from
[0183] R 1 , R 2 , R 3 , R 4 , R 6 , L 1 , L 2 and n are as defined in the first aspect of the present invention.
[0184] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0185]
[0186] Among them, ring B, R 1 , R 2 , R 3 , R 4 , R 6 and n are as defined in the first aspect of the present invention.
[0187] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0188]
[0189] Among them, ring B, R 1 , R 2 , R 3 , R4 , m and n are defined as described in the first aspect of the present invention.
[0190] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0191]
[0192] Among them, ring B, R 1 , R 2 , R 3 , R 4 , R 6 and n are as defined in the first aspect of the present invention.
[0193] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0194]
[0195] Among them, ring B, R 1 , R 2 , R 3 , R 4 , m and n are defined as described in the first aspect of the present invention.
[0196] In a preferred embodiment of the present invention, the ring B is selected from a 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms; the heteroatoms are selected from N, O and S; when there are multiple heteroatoms, the heteroatoms are the same or different.
[0197] In a preferred embodiment of the present invention, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group may be saturated or unsaturated but is not aromatic.
[0198] In a preferred embodiment of the present invention, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group is saturated.
[0199] In a preferred embodiment of the present invention, the ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridodihydropyridine, pyridomorpholine, pyridopyridine, pyridopyrrolidine.
[0200] In a preferred embodiment of the present invention, the ring B is selected from pyridine, pyrimidine, pyridazine, pyridodihydropyridine, and pyridopiperidine.
[0201] In a preferred embodiment of the present invention, the ring B is selected from
[0202] In a preferred embodiment of the present invention, the ring B is selected from a 5-10 membered heteroaryl group containing 1, 2, or 3 heteroatoms;
[0203] The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;
[0204] Preferably, ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridomorpholine, pyridopiperidine, pyridopyrrolidine;
[0205] More preferably, ring B is selected from pyridine, pyrimidine, pyridazine, pyridopiperidine.
[0206] In a preferred embodiment of the present invention, the ring B is selected from
[0207] In a preferred embodiment of the present invention, Selected from
[0208] In a preferred embodiment of the present invention, Selected from
[0209] In a preferred embodiment of the present invention, the L 1 Does not exist, L 2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R 2 Not tert-butyl,
[0210] In a preferred embodiment of the present invention, the L 1 Does not exist, L 2 is methylene, X 1 N, R 2 Methoxy, group for When R 3 Selected from
[0211] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0212]
[0213] Among them, R 2 Not tert-butyl,
[0214] R 1 , R 3 , R a is as defined in the first aspect of the present invention;
[0215] When R 3 is selected from 4-membered heterocycloalkyl; when the heteroatom is selected from O or S, R 1 With R 2 Not at the same time C 1-6 alkyl;
[0216] When R 1 is methyl, R 2 is methoxy, R a When both are hydrogen, R 3 Selected from
[0217] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0218]
[0219] Among them, at least one R a is deuterium (D), with a maximum of two R a is deuterium (D);
[0220] R 1 , R 2 , R 3 is as defined in the first aspect of the present invention.
[0221] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0222]
[0223] Among them, R 1 , R 2 , R 3 is as defined in the first aspect of the present invention;
[0224] When R 3 is selected from 4-membered heterocycloalkyl; when the heteroatom is selected from O or S, R 1 With R 2 Not at the same time C 1-6 alkyl.
[0225] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0226]
[0227] Among them, R 2 Not tert-butyl,
[0228] R 1 , R 3 is as defined in the first aspect of the present invention;
[0229] When R 3 is selected from 4-membered heterocycloalkyl; when the heteroatom is selected from O or S, R 1 With R 2 Not at the same time C 1-6 alkyl;
[0230] When R 1 is methyl, R 2 When it is methoxy, R 3 Selected from
[0231] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0232]
[0233] Among them, R 1 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 The cycloalkyl group is substituted with 1 to 4 deuterium (D);
[0234] R 2 , R 3 is as defined in the first aspect of the present invention.
[0235] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0236]
[0237] Among them, R 1 , R 2 , R 3 is as defined in the first aspect of the present invention;
[0238] When R 3 is selected from 4-membered heterocycloalkyl; when the heteroatom is selected from O or S, R 1 With R 2 Not at the same time C 1-6 alkyl.
[0239] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0240]
[0241] Wherein, ring D is selected from a 5-6 membered heteroolefin ring; the 5-6 membered heteroolefin ring contains 1 or 2 O;
[0242] R 1 , R 3 is as defined in the first aspect of the present invention.
[0243] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0244]
[0245] Among them, R 1 , R 3 is as defined in the first aspect of the present invention.
[0246] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0247]
[0248] Among them, R 1 , R 3 is as defined in the first aspect of the present invention.
[0249] In a preferred embodiment of the present invention, the R 1 Selected from deuterium (D), halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy;
[0250] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.
[0251] In a preferred embodiment of the present invention, the R 1 Selected from deuterium (D), F, methyl, -CD 3 , cyclopropyl, methoxy.
[0252] In a preferred embodiment of the present invention, p is selected from 0, 1, 2, and 3.
[0253] In a preferred embodiment of the present invention, said p is selected from 1 and 2.
[0254] In a preferred embodiment of the present invention, the R 1 Selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy;
[0255] The R 1 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0256] Preferably, R 1 Selected from F, methyl, cyclopropyl, methoxy.
[0257] In a preferred embodiment of the present invention, the R 2 Selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl;
[0258] The C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0259] m is selected from 0, 1 or 2.
[0260] In a preferred embodiment of the present invention, the R 2 , R 6 are independently selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl;
[0261] The C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7Cycloalkyl; when there are multiple substituents, the substituents are the same or different.
[0262] In a preferred embodiment of the present invention, the R 2 , R 6 Each is independently selected from H, cyano, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl; the methyl, isopropyl, methoxy, cyclopropyl or azetidinyl is substituted by 0, 1, 2 or 3 deuterium (D), F, Cl, Br or hydroxyl.
[0263] In a preferred embodiment of the present invention, the R 2 , R 6 Each independently selected from H, cyano, methyl, methoxy, trifluoromethyl, -CHF 2 、-O-CD 3 , cyclopropyl,
[0264] In a preferred embodiment of the present invention, the R 2 and R 6 Together with the carbon atom connected thereto, it forms a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains 1, 2 or 3 heteroatoms; the heteroatoms are selected from O, N, S, and P.
[0265] In a preferred embodiment of the present invention, the R 2 and R 6 Together with the carbon atom to which it is attached, it forms a 5-6 membered heteroolefin ring containing at least one O atom.
[0266] In a preferred embodiment of the present invention, the R 2 and R 6 Together with the carbon atom it is attached to,
[0267] In a preferred embodiment of the present invention, the R 2 and R 2 Together with the carbon atom connected thereto, it forms a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains 1, 2 or 3 heteroatoms; the heteroatoms are selected from O, N, S, and P.
[0268] In a preferred embodiment of the present invention, the R 2 and R 2 Together with the carbon atom to which it is attached, it forms a 5-6 membered heteroolefin ring containing at least one O atom.
[0269] In a preferred embodiment of the present invention, the R 2 and R 2 Together with the carbon atom it is attached to,
[0270] In a preferred embodiment of the present invention, the R 2 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl;
[0271] The R 2 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0272] m is selected from 0, 1 or 2;
[0273] Preferably, R 2 is selected from H, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl;
[0274] The R 2 Substituted with 0, 1 or 2 F, Cl, Br or hydroxy groups.
[0275] In a preferred embodiment of the present invention, the R 2 is selected from H, CN, methyl, methoxy, cyclopropyl, trideuterated methoxy, difluoromethyl, trifluoromethyl,
[0276] In a preferred embodiment of the present invention, X 1 is selected from N or CH.
[0277] In a preferred embodiment of the present invention, the ring D is selected from a 5-8 membered heterocyclic ring containing at least one O atom; the 5-8 membered heterocyclic ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.
[0278] In a preferred embodiment of the present invention, the ring D is selected from a 5-8 membered heterocycloalkyl group containing at least one O atom.
[0279] In a preferred embodiment of the present invention, the ring D is selected from dioxane or
[0280] In a preferred embodiment of the present invention, the L 1 Does not exist or is selected from R a The replaced C1-3 Alkylene.
[0281] In a preferred embodiment of the present invention, the L 1 Not present or selected from methylene, carbonyl, -CHD-, -CD 2 -、-CH(CH 3 )-.
[0282] In a preferred embodiment of the present invention, the L 1 is absent or selected from methylene, carbonyl, -CH(CH 3 )-.
[0283] In a preferred embodiment of the present invention, the L 1 Does not exist or is selected from R a The replaced C 1-3 Alkylene;
[0284] Preferably, the L 1 Not present or selected from alkylene, -CH(CH 3 )-.
[0285] In a preferred embodiment of the present invention, the L 2 Does not exist or is selected from R a The replaced C 1-3 Alkylene.
[0286] In a preferred embodiment of the present invention, the L 2 Not present or selected from methylene, carbonyl, -CHD-, -CD 2 -、-CH(CH 3 )-.
[0287] In a preferred embodiment of the present invention, the L 2 is absent or selected from methylene, carbonyl, -CH(CH 3 )-.
[0288] In a preferred embodiment of the present invention, the L 2 Does not exist or is selected from R a The replaced C 1-3 Alkylene;
[0289] Preferably, the L 2 Not present or selected from alkylene, -CH(CH 3 )-.
[0290] In a preferred embodiment of the present invention, Z is selected from NR b , O or S; said R b Selected from hydrogen, deuterium (D), -C 0-3 Alkyl-S(=O) 2-C 0-3 Alkyl-, -C 0-3 Alkyl-P(=O) 2 -C 0-3 Alkyl-, C 1-3 Alkyl or 3-4 membered heterocycloalkyl.
[0291] In a preferred embodiment of the present invention, Z is selected from NH or O.
[0292] In a preferred embodiment of the present invention, Selected from (like ),
[0293] In a preferred embodiment of the present invention, R 3 Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;
[0294] In a preferred embodiment of the present invention, the R 3 Selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 4-6 Heterocycloalkyl; said R 3 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy.
[0295] In a preferred embodiment of the present invention, the R 3 Selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy; said R 3 Optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy.
[0296] In a preferred embodiment of the present invention, the R 3 Selected from C 4-6 Heterocycloalkyl; said R 3 Optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo. In a preferred embodiment of the present invention, said R 3 Selected from cyano, C 1-6Alkyl, C substituted by hydroxy 1-6 Alkyl, C 1-6 Alkyl-C 1-3 Alkoxy-C 1-6 Alkoxy, C 4-6 Heterocycloalkyl, C substituted by halogen 4-6 Heterocycloalkyl, C substituted by oxo (=O) 4-6 Heterocycloalkyl.
[0297] In a preferred embodiment of the present invention, the R 3 is selected from cyano, methyl, ethyl, propyl, isopropyl, oxetanyl, tetrahydropyran, piperazine,
[0298] In a preferred embodiment of the present invention, the R 3 Selected from cyano, ethyl,
[0299] In a preferred embodiment of the present invention, the R 3 Selected from C 4-6 Heterocycloalkyl;
[0300] The R 3 Optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo; when there are multiple substituents, the substituents are the same or different;
[0301] Preferably, R 3 Selected from oxetane, piperazine,
[0302] More preferably, R 3 Selected from
[0303] In a preferred embodiment of the present invention, the R 3 Selected from cyano, ethyl, (like ),
[0304] In a preferred embodiment of the present invention, the R 4 Selected from deuterium (D), halogen, oxo (=O), hydroxyl, CN, C 1-3 Alkyl, C 3-5 Cycloalkyl; said R 4 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7.
[0305] In a preferred embodiment of the present invention, the R 4 is selected from deuterium (D), oxo (═O); n is selected from 0 or 1.
[0306] In a preferred embodiment of the present invention, the R 4 Selected from halogen, hydroxyl, C 1-3 Alkyl, C 3-5 Cycloalkyl;
[0307] The R 4 Optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;
[0308] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
[0309] Preferably, n is selected from 0.
[0310] In a preferred embodiment of the present invention, the compound comprises:
[0311]
[0312]
[0313]
[0314] In a preferred embodiment of the present invention, the compound comprises:
[0315]
[0316] The second aspect of the present invention is a pharmaceutical composition, comprising the compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug; and a pharmaceutically acceptable carrier.
[0317] In a third aspect of the present invention, the use of the compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the use of the pharmaceutical composition as described in the second aspect, the use includes:
[0318] Regulation of α5-GABA A Receptors;
[0319] and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases;
[0320] And / or, preparing a method for regulating α5-GABA A Receptor, and / or prevention and / or treatment of α5-GABA A A drug, pharmaceutical composition or preparation for a receptor-related disease.
[0321] Provided is a compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the pharmaceutical composition as described in the second aspect, which is expected to be used for pain, Alzheimer's disease, multi-infarct dementia or stroke.
[0322] Pain that should be mentioned is neuropathic pain, inflammatory pain or cancer pain.
[0323] The pain that should be mentioned is selected from the group consisting of headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, musculoskeletal pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune diseases, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis.
[0324] Infectious diseases which should be mentioned are selected from AIDS or postherpetic neuralgia.
[0325] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention.
[0326] Beneficial Effects
[0327] The present inventors have unexpectedly developed a compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof through extensive and in-depth research.
[0328] The present invention provides a compound of formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, wherein the compound of formula I has an effect on α5-GABA A The receptor has a significant regulatory effect and can treat diseases caused by α5-GABA A Receptor-mediated diseases or conditions show excellent pharmacokinetic properties and have high safety and drugability.
[0329] The present invention provides a method for preparing the compound shown in I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs and intermediates. The method is simple to operate, high in yield and purity, and can be used for industrial production of medicines. BRIEF DESCRIPTION OF THE DRAWINGS
[0330] Figure 1 , test compounds on the thermal pain threshold of rats in the rat CFA inflammatory pain model.
[0331] Definition and explanation of terms
[0332] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in examples, etc., can be arbitrarily combined and combined with each other. The group definitions and compound structures after such combination and combination shall fall within the scope recorded in the specification of this application.
[0333] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter of the claims pertains. Unless otherwise indicated, all patents, patent applications, and publications cited herein are incorporated herein by reference in their entirety. If there are multiple definitions of a term herein, the definition in this chapter shall prevail.
[0334] It should be understood that the above brief description and the detailed description below are exemplary and are only used for explanation, and do not impose any restrictions on the subject matter of the present invention. In this application, unless otherwise specifically stated, the use of the singular also includes the plural. It must be noted that unless otherwise clearly stated in the text, the singular form used in this specification and claims includes the plural form of the referred thing. It should also be noted that unless otherwise stated, the "or" and "or" used mean "and / or". In addition, the term "including" and other forms, such as "including", "containing" and "containing" are not restrictive.
[0335] Definitions of standard chemical terms can be found in references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4 THE ED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise stated, conventional methods within the technical scope of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless specifically defined, the terms used herein in the relevant descriptions of analytical chemistry, organic synthetic chemistry, and drugs and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and in the treatment of patients. For example, the manufacturer's instructions for use of the kit can be used, or the reaction and purification can be carried out in a manner known in the art or in accordance with the description of the present invention. The above-mentioned techniques and methods can usually be implemented according to the descriptions in the multiple summaries and more specific documents cited and discussed in this specification, according to conventional methods well known in the art. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural parts and compounds.
[0336] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. 2 O is equivalent to OCH 2 As used herein, Represents the attachment site of a group. As used herein, "R 1 ”, “R1” and “R 1 " have the same meaning and can be used interchangeably. 2 Other symbols and similar definitions have the same meaning.
[0337] The section headings used herein are only for the purpose of organizing the article and should not be interpreted as limitations on the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals and papers, are incorporated herein by reference in their entirety.
[0338] In addition to the foregoing, when used in the specification and claims of the present application, the following terms have the meanings indicated below unless otherwise specifically stated.
[0339] When the numerical range described in the specification and claims of this application is understood as an "integer", it should be understood that the two endpoints of the range and each integer in the range are recorded. For example, "an integer from 1 to 6" should be understood as recording each integer of 0, 1, 2, 3, 4, 5 and 6.
[0340] In the present application, when indicating the number of substituents, the term "one or more" refers to one substitution to the maximum possible number of substitutions, i.e., replacing one hydrogen to all hydrogens are replaced by substituents. When indicating the number of substituents, the term "1-4" refers to 1, 2, 3 or 4 substitutions, i.e., 1, 2, 3 or 4 hydrogens are replaced by substituents.
[0341] In the present application, "saturated, partially saturated or unsaturated" includes substituents saturated with hydrogen, substituents completely unsaturated with hydrogen and substituents partially saturated with hydrogen.
[0342] As used herein, the term "halogen" by itself or as part of another substituent refers to fluorine, chlorine, bromine, iodine.
[0343] As used herein, the term "hydroxy" by itself or as part of another substituent refers to -OH.
[0344] As used herein, the term "cyano" by itself or as part of another substituent refers to -CN.
[0345] As used herein, the term "amino" when used alone or as part of another substituent group refers to -NH 2 .
[0346] In the present application, the term "alkyl" means a straight or branched hydrocarbon chain group consisting of only carbon atoms and hydrogen atoms, having, for example, 1 to 6 carbon atoms and connected to the rest of the molecule by a single bond, either alone or as part of other substituents. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl. Alkyl groups may be unsubstituted or substituted with one or more suitable substituents. Alkyl groups may also be isotopic isomers of natural abundance alkyl groups rich in isotopes of carbon and / or hydrogen (i.e., deuterium or tritium).
[0347] In this application, the term "C α-β "Alkyl" refers to an alkyl group containing a minimum of α and a maximum of β carbon atoms in a branched or linear relationship or any combination of the three, where α and β represent integers, and can also be represented by "C α- C β The alkyl groups described in this section may also contain one or two double bonds or triple bonds. 0 The designation of alkyl indicates a direct bond. 1-6 Examples of alkyl groups include, but are not limited to, the following:
[0348] In this application, "benzo group", alone or in combination, refers to a divalent group C 4 H 4=, one of which is -CH=CH-CH=CH-, which forms a benzene-like ring when attached to another ring at the ortho position, such as tetralin, indole, etc.
[0349] In this application, the term "C α-β "Haloalkyl" refers to an alkyl group as described above wherein any number (at least one) of the hydrogen atoms attached to the alkyl chain are replaced by fluorine, chlorine, bromine or iodine.
[0350] As used herein, the term "alkoxy" by itself or as part of another substituent refers to the group -OR Q , where R Q is "alkyl" as defined above.
[0351] In the present application, the term "oxo" alone or as part of other substituents refers to the replacement of two hydrogen atoms on a methylene group by oxygen, that is, the methylene group is replaced by a carbonyl group, representing =0.
[0352] As used herein, the term "thio" by itself or as part of another substituent refers to the replacement of two hydrogen atoms on a methylene group with sulfur, representing =S.
[0353] As used herein, the term "cycloalkyl" or "carbocyclyl" when used alone or as part of another substituent refers to a cyclic alkyl group. m -C n Cycloalkyl" or "C m-n "Cycloalkyl" is understood to mean a saturated, unsaturated or partially saturated carbon ring having m to n atoms, but which is not aromatic. For example, "3-15 membered cycloalkyl" or "C 3 -C 15 "Cycloalkyl" refers to a cyclic alkyl group containing 3 to 15, 3 to 9, 3 to 6 or 3 to 5 carbon atoms, which may contain 1 to 4 rings. "5-8 membered cycloalkyl" contains 5-8 carbon atoms. It includes monocyclic, bicyclic, tricyclic, spirocyclic or bridged rings. Examples of unsubstituted cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl, or a bicyclic hydrocarbon group such as a decalin ring. The cycloalkyl group may be substituted with one or more substituents. In some embodiments, the cycloalkyl group may be a cycloalkyl group fused to an aryl or heteroaryl group. The term "C 3 -C 6 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms, including fused or bridged polycyclic ring systems. For example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
[0354] In the present application, the term "heterocycloalkyl" or "heterocyclyl" when alone or as part of other substituents refers to a cycloalkyl group in which one or more (in some embodiments, 1 to 3, such as 1, 2 or 3) carbon atoms are replaced by heteroatoms, such as but not limited to N, O, S and P. "Heterocycloalkyl" or "heterocyclyl" can be saturated or unsaturated, but not aromatic. "Heterocycloalkyl" or "heterocyclyl" can also contain 1, 2 or 3 rings, including bridged rings and spirocyclic structures. The term "3-10 membered heterocyclyl" or "3-10 membered heterocycloalkyl" should be understood to mean a monocyclic, bicyclic or tricyclic ring having 3 to 10 atoms (e.g., 3, 4, 5, 6, 7, 8, 9, 10), wherein the heteroatoms are preferably selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heterocyclyl exceeds 1, these heteroatoms are not adjacent to each other. The term "C 4-10 "Heterocycloalkyl" is understood to mean a monocyclic, bicyclic or tricyclic ring having 4 to 10 atoms (e.g. 4, 5, 6, 7, 8, 9, 10), having 1 to 3 heteroatoms, preferably selected from N, O and S, exemplarily selected from 3-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl, 3-7 membered heterocycloalkyl, 3-9 membered heterocycloalkyl, 4-10 membered heterocycloalkyl. Examples of the term heterocycloalkyl include, but are not limited to, oxetanyl, azetidinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl.
[0355] In this application, the term "C α-β "Cycloalkenyl" refers to a monocyclic group having α to β atoms, a double bond, but no aromaticity. Examples of cycloalkenyl are cyclopropene, cyclobutene, cyclohexene, cyclobutadiene, cyclopentadiene, cycloheptatriene, cyclooctatetraene, etc.
[0356] In the present application, the term "heteroalkene ring" when used alone or as part of other substituents refers to a monocyclic group with heteroatoms (the monocyclic group has double bonds but is not aromatic), preferably a monocyclic ring containing 1, 2 or 3 ring heteroatoms independently selected from N, O and S. Examples of heterocycloalkenyl groups are: dihydrofuranyl, dihydrothienyl, dihydropyrrolyl, dioxolyl, dihydroimidazolyl, dihydropyrazolyl, dihydrothiazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydrotetrazolyl, tetrahydropyridinyl, 3,4-dihydro-2H-pyran, pyranyl, thiopyranyl, dihydropyridinyl, dihydropyrazinyl, dihydropyrimidinyl, oxazinyl, dihydrotetrazolyl, etc. The term "heteroalkene ring" can be used interchangeably with the term "heterocycloalkenyl".
[0357] In the present application, the term "aryl" or "aromatic ring" refers to a monovalent aromatic carbocyclic ring system containing 6-14, preferably 6-10 carbon atoms and having at least one aromatic ring or multiple fused rings in which at least one ring is an aromatic ring, when used alone or as part of other substituents. Examples of aryl include, but are not limited to, phenyl, naphthyl, biphenyl or indanyl, etc.
[0358] In the present application, the term "5-14 membered heteroaromatic ring" or "5-14 membered heteroaryl" when alone or as part of other substituents means a stable monocyclic, bicyclic or tricyclic ring having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein at least one ring is aromatic and at least one ring contains 1-5 heteroatoms independently selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heteroaryl exceeds 1, these heteroatoms are not adjacent to each other. The 5-14 membered heteroaryl can be attached to the rest of the molecule through a heteroatom or a carbon atom. 5-14 membered heteroaryl groups within the scope of this definition include, but are not limited to, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolyl, indolyl, isoindolyl, 1H,3H-1-oxoisoindolyl, benzotriazolyl, furanyl, thienyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, benzothienyl, benzofuranyl, benzodioxane, benzodioxine, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzotriazolyl, benzothiophene, benzofuranyl, benzodioxane, benzodioxine, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzotri ... 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,4,5-tetrazinyl, tetrazolyl, xanthenyl, phenazinyl, phenothiazinyl, phenoxazinyl, aza-zepinyl, oxa-zepinyl and thia-zepinyl. The term "5-10 membered heteroaromatic ring" or "5-10 membered heteroaryl" is understood as a monocyclic, bicyclic or tricyclic ring having 5 to 10 atoms, wherein at least one ring is aromatic and contains at least 1 to 5 heteroatoms independently selected from N, O and S. In the present application, the term "5-10 membered heteroaromatic ring" or "5-10 membered heteroaryl" shall include 5-10 membered heteroaromatic ring monocyclic ring, fused bicyclic ring having 5 to 10 atoms, and the fused bicyclic ring having 5 to 10 atoms includes 5 membered heteroaromatic ring and C 5-7 Heteroaromatic ring, 6-membered heteroaromatic ring and C 5-6 Heteroaromatic ring, 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7Heterocycloalkyl may be saturated or unsaturated, but not aromatic. Examples of 5-10 membered heteroaromatic rings include, but are not limited to, furanyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, diazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, etc.
[0359] In the present application, the term "monocyclic" when alone or as part of other substituents means a group having only one ring, which may be saturated, unsaturated or partially saturated, and may be a carbocyclic ring (all ring atoms are carbon atoms) or a heterocyclic ring (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S).
[0360] In the present application, the term "bicyclic" means a group having two connected rings, either alone or as part of other substituents. Bicyclic rings can be carbocyclic rings (all ring atoms are carbon atoms) or heterocyclic rings (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S). Both rings can be aliphatic (e.g., decalin and norbornane), or can be aromatic (e.g., naphthalene), or a combination of aliphatic and aromatic (e.g., tetralin). Bicyclic rings include (a) spirocyclic compounds, in which the two rings share only one single atom (spiro atom, which is usually a quaternary carbon). Examples of spirocyclic compounds include, but are not limited to:
[0361]
[0362] It also includes spirocycloalkyl groups that share a spiro atom with a heterocycloalkyl group. Non-limiting examples include:
[0363]
[0364] (b) Fused bicyclic compounds, where the two rings share two adjacent atoms. In other words, the rings share one covalent bond, i.e., the bridgehead atoms are directly connected (e.g., α-thujene and decalin). Examples of fused bicyclic rings include, but are not limited to:
[0365]
[0366] and (c) bridged bicyclic compounds, wherein the two rings share three or more atoms and the two bridgehead atoms are separated by a bridge comprising at least one atom. For example, norbornane, also known as bicyclo[2.2.1]heptane, can be considered as a pair of cyclopentane rings, each ring sharing three of their five carbon atoms. Examples of bridged bicyclic rings include, but are not limited to:
[0367]
[0368] In the present application, the term "inert solvent" includes, but is not limited to: toluene, benzene, water, methanol, ethanol, isopropanol, ethylene glycol, N-methylpyrrolidone, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, chloroform, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, or a combination thereof.
[0369] Compounds provided herein include intermediates that can be used to prepare compounds provided herein, which contain reactive functional groups (such as but not limited to carboxyl, hydroxyl and amino moieties), and also include protected derivatives thereof. "Protected derivatives" are those compounds in which one or more reactive sites are blocked by one or more protecting groups (also referred to as protecting groups). Suitable carboxyl moiety protecting groups include benzyl, tert-butyl, etc., and isotopes, etc. Suitable amino and amido protecting groups include acetyl, trifluoroacetyl, tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable hydroxyl protecting groups include benzyl, etc. Other suitable protecting groups are well known to those of ordinary skill in the art.
[0370] In the present application, the term "optionally substituted by" or "optionally substituted by" means that the specified group is unsubstituted or substituted by one or more substituents independently selected from possible substituents. For example, "aryl is optionally substituted by 1-4 substituents independently selected from the following groups: halogen, cyano, hydroxyl, C 1-6 "Alkyl" means that the aryl group is unsubstituted or substituted by 1, 2, 3 or 4 substituents independently selected from the following groups: halogen, cyano, hydroxyl, C 1-6 The term "alkyl" refers to an alkyl group, and the description includes both substituted and unsubstituted aryl groups.
[0371] In the present application, the term "salt" or "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues within the scope of sound medical judgment without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0372] In this application, the term "pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid or organic acid that retains the biological effectiveness of the free base without other side effects. "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or organic base that retains the biological effectiveness of the free acid without other side effects. In addition to pharmaceutically acceptable salts, other salts are contemplated by the present invention. They can serve as intermediates in the purification of compounds or in the preparation of other pharmaceutically acceptable salts or can be used for the identification, characterization or purification of the compounds of the present invention.
[0373] In the present application, the term "amine salt" refers to the product obtained by neutralizing an alkyl primary amine, a secondary amine or a tertiary amine with an acid. The acid includes the inorganic acid or organic acid described in the present application.
[0374] In the present application, the term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in molecules, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.
[0375] Depending on the choice of starting materials and methods, the compounds of the invention may exist in the form of one of the possible isomers or a mixture thereof, for example as a pure optical isomer, or as a mixture of isomers, such as a racemic and diastereomeric mixture, depending on the number of asymmetric carbon atoms. When describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule with respect to the chiral center (or multiple chiral centers) in the molecule. The prefixes D and L or (+) and (–) are the symbols used to specify the rotation of plane polarized light caused by the compound, where (–) or L indicates that the compound is levorotatory. Compounds prefixed with (+) or D are dextrorotatory.
[0376] When the bonds to the chiral carbon in the formula of the present invention are depicted as straight lines, it should be understood that both the (R) and (S) configurations of the chiral carbon and the enantiomerically pure compounds and mixtures thereof produced therefrom are included within the scope of the general formula. The graphic representation of racemates or enantiomerically pure compounds herein is from Maehr, J. Chem. Ed. 1985, 62: 114-120. The absolute configuration of a stereocenter is indicated by a wedge-shaped bond and a dashed bond.
[0377] In the present application, the term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom in two positions in a molecule. The compounds of the present invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Prototropic tautomers arise from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium, and attempts to separate a single tautomer generally produce a mixture whose physicochemical properties are consistent with a mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form is predominant; whereas in phenols, the enol form is predominant. The present invention encompasses all tautomeric forms of the compounds.
[0378] In this application, the term "pharmaceutical composition" refers to a preparation of a compound of the present invention and a medium generally accepted in the art for delivering a biologically active compound to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote administration of an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0379] In this application, the term "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or livestock use.
[0380] In the present application, the term "solvate" means that the compound of the present invention or a salt thereof includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent forces between molecules. When the solvent is water, it is a hydrate.
[0381] In the present application, the term "prodrug" refers to a compound of the present invention that can be converted into a biologically active compound under physiological conditions or by solvolysis. The prodrug of the present invention is prepared by modifying the functional groups in the compound, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. The prodrug includes a compound formed by connecting a hydroxyl or amino group in the compound of the present invention to any group. When the prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug is cleaved to form a free hydroxyl group and a free amino group, respectively.
[0382] The compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound, said isotopes having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number that predominantly occurs in nature. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H or D), tritium ( 3 H or T), iodine-125 ( 125 I) or C-14( 14 C). All isotopic variations of the compounds of the invention, whether radioactive or not, are included within the scope of the invention. Isotopic variants may provide certain therapeutic advantages, such as deuterium enrichment may increase in vivo half-life or reduce dosage requirements, or may provide a standard compound useful for characterization of biological samples. Isotopically enriched compounds within Formula I may be prepared without undue experimentation by conventional techniques well known to those skilled in the art, or by methods analogous to those described in the routes and examples herein, using appropriate isotopically enriched reagents and / or intermediates.
[0383] In this application, the term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the type of the term "excipient" include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, and diluents. Excipients can enhance the handling characteristics of a pharmaceutical formulation, i.e., make the formulation more suitable for direct compression by increasing fluidity and / or adhesion.
[0384] As used herein, the term "treatment" and other similar synonyms include the following meanings:
[0385] (i) preventing a disease or condition from occurring in a mammal, particularly where such mammal is susceptible to the disease or condition but has not yet been diagnosed as having the disease or condition;
[0386] (ii) inhibiting a disease or condition, i.e. arresting its development;
[0387] (iii) alleviate the disease or condition, that is, cause regression of the disease or condition; or
[0388] (iv) alleviating the symptoms caused by the disease or condition.
[0389] The reaction temperature of each step can be appropriately selected according to the solvent, starting materials, reagents, etc., and the reaction time can also be appropriately selected according to the reaction temperature, solvent, starting materials, reagents, etc. After the reaction of each step is completed, the target compound can be separated and purified from the reaction system by common methods, such as filtration, extraction, recrystallization, washing, silica gel column chromatography, etc. In the case of not affecting the next step reaction, the target compound can also be directly used in the next step reaction without separation and purification. DETAILED DESCRIPTION
[0390] The present invention is further described below in conjunction with specific examples. It should be understood that the following description is only the most preferred embodiment of the present invention and should not be considered as limiting the scope of protection of the present invention. On the basis of a full understanding of the present invention, the experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Those skilled in the art may make non-essential changes to the technical solution of the present invention, and such changes should be deemed to be included in the scope of protection of the present invention.
[0391] This application has the following definitions:
[0392] Symbol or unit:
[0393] IC 50 : Half inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved
[0394] M: mol / L, for example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) means a n-butyllithium n-hexane solution with a molar concentration of 2.5 mol / L
[0395] N: equivalent concentration, for example, 2N hydrochloric acid means 2 mol / L hydrochloric acid solution
[0396] RT: retention time
[0397] Reagents:
[0398] PE: Petroleum ether
[0399] EA: also written as EtOAc, ethyl acetate
[0400] DCM: dichloromethane
[0401] MeOH: Methanol
[0402] DMF: N,N-dimethylformamide
[0403] DIPEA: N,N-diisopropylethylamine
[0404] Pd 2 (dba) 3 :Tris(dibenzylideneacetone)dipalladium
[0405] Pd(dppf)Cl 2 :(1,1'-bis(diphenylphosphino)ferrocene)palladium dichloride
[0406] Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
[0407] HATU: 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
[0408] Test method:
[0409] LCMS: Liquid chromatography-mass spectrometry
[0410] TLC: Thin layer chromatography
[0411] Intermediates A1 and A2: Preparation of 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile and 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile
[0412] 6-Chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (Intermediate A1)
[0413]
[0414] 6-Chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (Intermediate A2)
[0415]
[0416] The synthetic routes of intermediates A1 and A2 are as follows:
[0417]
[0418] Step 1: Synthesis of 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile and 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile
[0419]
[0420] 3,6-Dichloropyridazine-4-carbonitrile (5.0 g, 28.7 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (4.0 g, 28.7 mmol) were added to 25 mL of n-butanol in sequence, and the mixture was heated to reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (PE / EA (V / V) = 3 / 1) to give 6-chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (320 mg) and 6-chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (3.4 g, yield: 49.6%).
[0421] LC-MS, M / Z(ESI+):261.0[M+H] +
[0422] Intermediate A3: Preparation of (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol
[0423]
[0424] The preparation method of intermediate A3 refers to patent WO2021121294A1.
[0425] Example 1: Preparation of target compound I-5
[0426] 3-(7-cyclopropyl-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0427]
[0428] The synthetic route of the target compound I-5 is as follows:
[0429]
[0430] Step 1: Synthesis of 3,6-dichloro-4-cyclopropylpyridazine
[0431]
[0432] To a suspension of 3,6-dichloropyridazine (10.00 g, 67.12 mmol) in water (300 mL) was added 10 mL of concentrated sulfuric acid and cyclopropanecarboxylic acid (5.85 mL, 73.7 mmol), heated at 70 °C and stirred with N 2 Degas. Add a solution of silver nitrate (2.28 g, 13.4 mmol) in 10 mL of water over 30 seconds, then add a solution of ammonium persulfate (46 g, 201.577 mmol) in 150 mL of water dropwise over 30 minutes. After reacting for 1 hour, LCMS showed that the reaction was complete, the mixture was cooled to room temperature and poured onto ice, ammonia was added dropwise to adjust the pH of the solution to 9, extracted 3 times with ethyl acetate (100 mL), the organic phases were combined, washed with saturated brine (100 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and dried, and the crude product was separated by column chromatography (PE / EA (V / V) = 2 / 3) to obtain 3,6-dichloro-4-cyclopropylpyridazine (6.83 g, yield: 54%).
[0433] Step 2: 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0434]
[0435] 3,6-dichloro-4-cyclopropylpyridazine (5.33 g, 28.3 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (4.0 g, 28.3 mmol) were added to 30 mL of n-butanol in sequence, heated under argon protection for 4 hours, the solvent was evaporated, the solid was slurried with 40 mL of dichloromethane for 2 hours, the insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EA (V / V) = 1 / 1) to obtain 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (600 mg, yield: 7.7%).
[0436] Step 3: 3-(7-cyclopropyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole
[0437]
[0438] At room temperature, 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.54 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (120 mg, 0.54 mmol) and cesium carbonate (354 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by reverse-phase high performance liquid chromatography (chromatographic column: SunFileTM Prep C18 OBDTM 5μm 30mm×150mm); mobile phase: A=acetonitrile, B=water; gradient: 1%-25%, 8 minutes) to obtain 3-(7-cyclopropyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (64.5 mg, yield: 25.9%).
[0439] LC-MS, M / Z(ESI+):460.2[M+H] +
[0440] 1 H NMR (400 MHz, CDCl 3 )δ7.53(s,1H),7.49(d,J=7.9Hz,1H),7.39(d,J=7.9Hz,1H),6.83(s,1H),5.61(s,2H),4.73(dt,J=18.4,6.3Hz,4H),3.76–3.70(m,1H),3.54( s,2H),3.11(t,J=5.9Hz,2H),2.74(t,J=6.0Hz,2H),2.58(s,3H),2.19(ddd,J=13.6,8.4,5.3Hz,1H),1.19–1.11(m,2H),0.84(q,J=5.1Hz,2H).
[0441] Example 2: Preparation of target compound I-9
[0442] 3-(7,8-dimethyl-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0443]
[0444] The synthetic route of the target compound I-9 is as follows:
[0445]
[0446] Step 1: 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0447]
[0448] 3,6-dichloro-4,5-dimethylpyridazine (1.5 g, 8.5 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (1.2 g, 8.5 mmol) were added to 10 mL of n-butanol in sequence, heated under argon protection for 4 hours, the solvent was evaporated, the solid was slurried with 20 mL of dichloromethane for half an hour, the insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EA (V / V) = 1 / 1) to obtain 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (1.2 g, yield: 52.9%).
[0449] Step 2: 3-(7,8-dimethyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0450]
[0451] At room temperature, 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.57 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (125 mg, 0.57 mmol) and cesium carbonate (370 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by reverse phase high performance liquid chromatography (chromatographic column: SunFileTM Prep C18 OBDTM 5μm 30mm×150mm); mobile phase: A=acetonitrile, B=water; gradient: 1%-25%, 8 minutes) to obtain 3-(7,8-dimethyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (31.6 mg, yield: 12%).
[0452] LC-MS, M / Z(ESI+):448.2[M+H] +
[0453] 1 H NMR (400 MHz, CDCl 3 )δ7.46(d,J=7.9Hz,1H),7.39(d,J=7.9Hz,1H),6.84(s,1H),5.55(s,2H),4.74(dt,J=17.8,6.3Hz,4H),3.78– 3.70(m,1H),3.54(s,2H),3.11(t,J=6.0Hz,2H),2.74(t,J=6.0Hz,2H),2.69(s,3H),2.57(s,3H),2.32(s,3H).
[0454] Example 3: Preparation of target compound I-11
[0455] 5-Cyclopropyl-3-(8-methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0456]
[0457] The synthetic route of the target compound I-11 is as follows:
[0458]
[0459] Step 1: 5-Cyclopropylisoxazole-3-carboxylic acid hydrazide
[0460]
[0461] Ethyl 5-cyclopropylisoxazole-3-carboxylate (5.00 g, 29.94 mmol) was dissolved in ethanol (25 mL), and then hydrazine hydrate (4.0 mL, 80%) was added. After the addition, the reaction solution was reacted at 100°C under nitrogen protection for 2 hours. LC-MS showed that the reaction was complete, and the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was washed with dichloromethane (50 mL), and then filtered to obtain a filter cake, and the filter cake was dried to obtain 5-cyclopropylisoxazole-3-carboxylic acid hydrazide (4.2 g, yield: 83%).
[0462] Step 2: 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-cyclopropylisoxazole
[0463]
[0464] 3,6-dichloro-4-methoxypyridazine (4.23 g, 23.8 mmol) and 5-cyclopropylisoxazole-3-carboxylic acid hydrazide (4.0 g, 23.8 mmol) were added to 30 mL of n-butanol in sequence, heated under argon protection for 4 hours, the solvent was evaporated, the solid was slurried with 40 mL of dichloromethane for half an hour, the insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EA (V / V) = 1 / 1) to obtain 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-cyclopropylisoxazole (190 mg, yield: 2.5%).
[0465] Step 3: 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0466]
[0467] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-cyclopropylisoxazole (150 mg, 0.51 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (113 mg, 0.51 mmol) and cesium carbonate (335 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was prepared by reverse-phase high performance liquid chromatography (chromatographic column: SunFileTM Prep C18 OBDTM 5μm 30mm×150mm); mobile phase: A=acetonitrile, B=water; gradient: 1%-25%, 8 minutes) to obtain 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)isoxazole (45 mg, yield: 25.9%).
[0468] LC-MS, M / Z(ESI+):476.2[M+H] +
[0469] 1 H NMR (400 MHz, CDCl 3 )δ7.44(d,J=7.9Hz,1H),7.37(d,J=7.9Hz,1H),6.75(s,1H),6.21(s,1H),5.52(s,2H),4.73(dt,J=18.4,6.4Hz,4H),4.12(s,3H),3 .76–3.69(m,1H),3.53(s,2H),3.11(t,J=6.0Hz,2H),2.73(t,J=6.0Hz,2H),2.18(ddd,J=16.9,8.3,5.1Hz,1H),1.18–1.08(m,4H).
[0470] Example 4: Preparation of target compound I-8
[0471] 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one
[0472]
[0473] The synthetic route of the target compound I-8 is as follows:
[0474]
[0475] Step 1: Synthesis of tert-butyl 3-oxopiperazine-1-carboxylate
[0476]
[0477] At room temperature, piperazine-2-one (10.0 g, 0.1 mol) was dissolved in DCM (100 mL), and then di-tert-butyl dicarbonate (21.8 g, 0.1 mol) was added. After the addition, the reaction solution was reacted at room temperature for 2 hours. LCMS showed that the reaction was complete. Water (200 mL) was added to the reaction solution, and then extracted three times with dichloromethane (100 mL). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EtOAc (v / v) = 4 / 1) to obtain tert-butyl 3-oxopiperazine-1-carboxylate (18 g).
[0478] Step 2: Synthesis of tert-butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate
[0479]
[0480] Under ice bath, tert-butyl 3-oxopiperazine-1-carboxylate (5g, 0.25mol) was dissolved in DMF (60mL), and then sodium hydride (1.8g, 0.37mol) was slowly added to the reaction, stirred for 30 minutes after addition, and then 1-(chloromethyl)-4-methoxybenzene (5.1g, 0.3mol) was added dropwise to the reaction, followed by stirring at room temperature for 2 hours. LCMS detected that the reaction was complete, 50mL of water was added to the reaction solution to quench the reaction, and then water (200mL) was added to the reaction solution, and then extracted three times with dichloromethane (100mL), the organic phases were combined, washed five times with water (100mL), washed with saturated brine (100mL), the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and dried, and the crude product was separated by column chromatography to obtain tert-butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate (6g).
[0481] Step 3: Synthesis of 1-(4-methoxybenzyl)piperazine-2-one
[0482]
[0483] At room temperature, tert-butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate (6.0 g, 18.75 mmol) was dissolved in dioxane (4 M, 30 mL) with hydrochloric acid, and the reaction solution was reacted at room temperature for 2 hours. After the reaction was completed as monitored by LCMS, the reaction solution was concentrated to obtain 1-(4-methoxybenzyl)piperazine-2-one (hydrochloride, 4 g), which was directly used in the next step without purification.
[0484] Step 4: Synthesis of methyl 6-(4-(4-methoxybenzyl)-3-oxopiperazin-1-yl)pyridazine-3-carboxylate
[0485]
[0486] At room temperature, methyl 6-chloropyridazine-3-carboxylate (1.25 g, 7.26 mmol) was dissolved in dioxane (20 mL), and then 1-(4-methoxybenzyl)piperazine-2-one (hydrochloride, 1.6 g, 7.27 mmol), Pd 2 (dba) 3 (665mg, 0.72mmol), Xantphos (420mg, 0.72mmol) and cesium carbonate (3.54g, 10.9mmol), react at 100°C for 16 hours under nitrogen protection. LCMS shows that the reaction is complete. The reaction solution is concentrated to obtain a crude product, and water (50mL) is added to the reaction solution, and then extracted three times with dichloromethane (30mL), the organic phases are combined, washed with saturated brine (40mL), and the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated and dried. The crude product is separated by column chromatography (EtOAc / PE (V / V) = 1:1) to obtain 6-(4-(4-methoxybenzyl)-3-oxopiperazine-1-yl)pyridazine-3-carboxylic acid methyl ester (0.78mg).
[0487] Step 5: Synthesis of 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one
[0488]
[0489] Under ice bath conditions, methyl 6-(4-(4-methoxybenzyl)-3-oxopiperazine-1-yl)pyridazine-3-carboxylate (0.78 mg, 2.19 mmol) was dissolved in tetrahydrofuran / ethanol (V / V=1 / 1) (10 mL), and then sodium borohydride (166.4 mg, 4.38 mmol) and calcium chloride (486.1 mg, 4.38 mmol) were added respectively. The reaction solution was reacted at room temperature for 16 hours, and LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product, which was directly separated by column chromatography (DCM / MeOH (V / V)=10:1) to obtain 4-(6-(hydroxymethyl)pyridazine-3-yl)-1-(4-methoxybenzyl)piperazine-2-one (0.51 g).
[0490] Step 6: Synthesis of 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one
[0491]
[0492] At room temperature, 3-(6-chloro-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (403 mg, 1.52 mmol), 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (500 mg, 1.52 mmol) and cesium carbonate (990 mg, 3.04 mmol) were dissolved in acetonitrile (10 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by column chromatography (DCM / MeOH (V / V) = 15 / 1) to obtain 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (220 mg).
[0493] Step 7: Synthesis of 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one
[0494]
[0495] At room temperature, 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (220 mg, 0.39 mmol) was dissolved in toluene (6 mL), and trifluoromethanesulfonic acid (0.5 mL) was added. The reaction was then placed at 110° C. for 2 hours. LCMS detected that the reaction was complete. The reaction solution was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (6.0 mg)
[0496] LC-MS, M / Z(ESI+):438.1[M+H] +
[0497] 1 H NMR (400 MHz, DMSO- d6 )δ8.15(s,1H),7.75(s,1H),7.72(d,J=9.6Hz,1H),7.30(d,J=9.6Hz,1H),7.04(s,1H),5 .59(s,2H),4.11(s,2H),3.96(s,3H),3.86–3.80(m,2H),3.30–3.29(m,2H),2.57(s,3H).
[0498] Example 5: Preparation of target compound I-12
[0499] 5-Methyl-3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0500]
[0501] The synthetic route of the target compound I-12 is as follows:
[0502]
[0503] Step 1: Synthesis of 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0504]
[0505] 3,6-Dichloropyridazine (1.0 g, 7.0 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (1.05 g, 7.0 mmol) were added to 10 mL of n-butanol in sequence, heated under argon protection for 4 hours, the solvent was evaporated, the solid was slurried with 10 mL of dichloromethane for half an hour, the insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EtOAc (V / V) = 1 / 1) to obtain 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (370 mg).
[0506] Step 2: Synthesis of 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0507]
[0508] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.63 mmol), (6-(oxane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (140 mg, 0.63 mmol) and cesium carbonate (414.8 mg, 1.12 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by high performance liquid phase to obtain 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)isoxazole (90 mg).
[0509] LC-MS, M / Z(ESI+):419.2[M+H] +
[0510] 1 H NMR (400 MHz, CDCl 3)δ8.07(d,J=9.8Hz,1H),7.46(d,J=7.8Hz,1H),7.39(d,J=7.9Hz,1H),6.97(d,J=9.8Hz,1H),6.84(s,1H),5.54(s,2H),4. 72(dt,J=18.4,6.3Hz,4H),3.72(p,J=6.4Hz,1H),3.53(s,2H),3.10(t,J=5.9Hz,2H),2.73(t,J=6.0Hz,2H),2.58(s,3H).
[0511] Example 6: Preparation of target compound I-14
[0512] 3-(8-Methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0513]
[0514] The synthetic route of the target compound I-14 is as follows:
[0515]
[0516] Step 1: Synthesis of 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0517]
[0518] 3,6-dichloro-4-methoxy-pyridinium (9.9 g, 55.6 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (7.8 g, 55.6 mmol) were added to 50 mL of n-butanol in sequence, heated under argon protection for 4 hours, the solvent was evaporated, the solid was slurried with 50 mL of dichloromethane for half an hour, the insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EtOAc=1 / 4, v / v) to obtain a crude product (2.7 g).
[0519] Step 2: Synthesis of 3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole
[0520]
[0521] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.51 mmol), (6-(oxane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (113 mg, 0.51 mmol) and cesium carbonate (333 mg, 1.01 mmol) were dissolved in acetonitrile (6 mL), and then the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (30 mg).
[0522] LC-MS, M / Z(ESI):450.2[M+H] +
[0523] 1 H NMR (400 MHz, CDCl 3 )δ7.47(d,J=7.8Hz,1H),7.39(d,J=7.8Hz,1H),7.26(s,1H),6.79(s,1H),5.57(s,2H),4.80-4.63(m,4H), 4.00(s,3H),3.71(t,J=6.6Hz,1H),3.52(s,2H),3.08(t,J=5.9Hz,2H),2.71(t,J=6.1Hz,2H),2.55(s,3H)
[0524] Example 7: Preparation of target compound I-15
[0525] 3-(7-methoxy-6-(1-(6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0526]
[0527] The synthetic route of the target compound I-15 is as follows:
[0528]
[0529] Step 1: Synthesis of 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethane-1-one hydrochloride
[0530]
[0531] Dissolve tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.85 g, 3.16 mmol) in anhydrous dioxane (10 mL), then weigh tributyl(1-ethoxyethylene)tin (1.37 g, 3.80 mmol), triethylamine (0.96 g, 9.49 mmol) and dichlorobistriphenylphosphine palladium (0.22 g, 0.32 mmol) into the above solution. Vacuum and replace with nitrogen three times, then react the reaction solution at 100°C for 16 hours under nitrogen protection. TLC (PE:EA (V / V) = 1:1) shows that the reaction is complete. The reaction solution was cooled to room temperature, diluted with water (10 mL), extracted three times with EtOAc (20 mL), the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and dried, and the crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 0%-50%) to obtain 2-(1-ethoxyvinyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester, and then the column chromatography separation product was concentrated under reduced pressure and dried, diluted with anhydrous dioxane (10 mL), and then 6N HCl (5 mL) was added, and the reaction solution was stirred at room temperature for 30 min. TLC (PE:EA (V / V) = 1:1) showed that the reaction was complete. The reaction solution was directly concentrated under reduced pressure and dried to give 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethan-1-one hydrochloride (0.60 g, crude product), which was directly used in the next step.
[0532] Step 2: Synthesis of tert-butyl 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0533]
[0534] Under ice bath conditions, 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethane-1-one hydrochloride (0.60 g, 2.41 mmol) was dissolved in anhydrous dichloromethane (10 mL), and then triethylamine (1.22 g, 12.04 mmol), di-tert-butyl dicarbonate (0.79 g, 3.61 mmol) and N,N-dimethylpyridin-4-amine (29.42 mg, 0.24 mmol) were weighed into the above solution, and the reaction solution was reacted at room temperature for 10 hours. TLC (PE:EA (V / V) = 3:1) showed that the reaction was complete. Water (15 mL) was added to the reaction solution, and it was extracted three times with EtOAc (20 mL). The organic phases were combined, washed with saturated brine (20 mL), and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered, concentrated under reduced pressure and spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 0% -40%) to give tert-butyl 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g).
[0535] Step 3: Synthesis of tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0536]
[0537] Under ice bath conditions, weigh 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester (0.32 g, 4.38 mmol) and dissolve it in methanol (5 mL), then add sodium borohydride (65.71 mg, 1.74 mmol) in batches. The reaction solution was reacted at room temperature for 2 hours. TLC (PE:EA=3:1) showed that the reaction was complete. Saturated NH 4 Cl solution (5 mL), extracted three times with EtOAc (10 mL), the organic phase was washed with saturated brine (10 mL), and washed with anhydrous Na 2 SO 4 The residue was dried, filtered, concentrated under reduced pressure and then spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 0% -50%) to give tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.25 g).
[0538] Step 4: Synthesis of tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0539]
[0540] At room temperature, weigh tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.14 g, 0.50 mmol) and dissolve it in acetonitrile (3 mL). Then add 3-(6-chloro-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (133.61 mg, 0.50 mmol) and cesium carbonate (0.49 g, 1.50 mmol). The reaction solution was reacted at 60°C for 10 minutes. TLC (PE:EA(V / V)=1:1) showed that the reaction was complete. Water (30 mL) was added to the reaction solution, and it was extracted three times with EtOAc (10 mL). The organic phase was washed with saturated brine (5 mL) and washed with anhydrous Na 2 SO 4 The reaction mixture was dried, filtered, concentrated under reduced pressure and spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc=0%-50%) to give tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g).
[0541] Step 5: Synthesis of 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride
[0542]
[0543] Under ice bath, weigh tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g) and dissolve it in ethyl acetate (3 mL), then add hydrochloric acid ethyl acetate (6 mL, 4 M). After the addition, the reaction solution was reacted under ice bath for 1 minute. TLC (PE:EA(V / V)=1:1) showed that the reaction was complete. The reaction solution was directly concentrated under reduced pressure and dried to obtain 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridine-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride (0.43 g, crude product).
[0544] Step 6: Synthesis of 3-(7-methoxy-6-(1-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole
[0545]
[0546] Under ice bath, 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride (0.43 g, 0.90 mmol) was dissolved in dichloroethane (5 mL), and then triethylamine (0.19 g, 1.80 mmol) was added. After the addition, the mixture was stirred for 30 minutes under the same conditions. Then, 3-oxetanone (70.96 mg, 0.98 mmol), sodium acetate borohydride (0.28 g, 1.34 mmol) and acetic acid (5.38 mg, 0.09 mmol) were added in sequence. After the addition, the reaction solution was warmed to room temperature and stirred for 16 hours under the same conditions. The reaction was completed by LCMS monitoring. Dichloromethane (10 mL) was added to the reaction solution, and the mixture was washed with water (5 mL) and saturated brine (5 mL) in sequence. The organic phase was concentrated under reduced pressure and dried. The residue was separated by normal phase silica gel column chromatography (PE / EtOAc=0%-50%) to give 3-(7-methoxy-6-(1-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (0.22 g).
[0547] LC-MS, M / Z(ESI):464.2[M+H] +
[0548] 1 H NMR (400 MHz, CDCl 3 ): δ7.39(d,1H),7.31(d,1H),7.18(s,1H),6.77(s,1H),6.23-6.18(m,1H),4.75-4.68(m,4H),4.01(s ,3H),3.73-3.66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H)
[0549] Example 8: Preparation of target compound I-17
[0550] 3-(5-methylisoxazol-3-yl)-N-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide
[0551]
[0552] The synthetic route of the target compound I-17 is as follows:
[0553]
[0554] Step 1: Synthesis of methyl 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylate
[0555]
[0556] Methyl 6-chloropyridazine-3-carboxylate (600 mg, 3.48 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (490 mg, 3.48 mmol) were added to 4 mL of n-butanol in sequence, and the mixture was heated to reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (PE / EA (V / V) = 3 / 1) to give methyl 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylate (580 mg).
[0557] LC-MS, M / Z(ESI):260.1[M+H] +
[0558] Step 2: Synthesis of 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid
[0559]
[0560] 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid methyl ester (580 mg, 2.23 mmol) and lithium hydroxide monohydrate (460 mg, 11.1 mmol) were added to 10 mL of a mixed solvent of tetrahydrofuran and water (V / V=1 / 1) in sequence, and the reaction was carried out at 50°C for 4 hours. After the reaction system was cooled to room temperature, the pH was adjusted to 5-6 with 1N hydrochloric acid, and the mixture was extracted three times with dichloromethane (10 mL). The organic phase was collected and concentrated to obtain a crude product, which was purified by a silica gel column (DCM / MeOH (V / V)=30 / 1) to obtain 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid (260 mg).
[0561] LC-MS, M / Z(ESI):246.1[M+H] +
[0562] Step 3: Synthesis of 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide
[0563]
[0564] 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid (260 mg, 1.05 mmol) was dissolved in anhydrous DMF (5 mL), and triethylamine (1.0 g, 10.5 mmol), HATU (600 mg, 1.5 mmol), and ammonium chloride (340 mg, 6.30 mmol) were added in sequence, and the mixture was reacted at room temperature for 16 hours. Water (10 mL) was added to the reaction system, and the mixture was extracted twice with dichloromethane (10 mL). The organic phase was collected and concentrated to obtain a crude product, which was purified by silica gel column (DCM / MeOH (V / V) = 30 / 1) to obtain 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (140 mg).
[0565] LC-MS, M / Z(ESI):245.1[M+H] +
[0566] Step 4: Synthesis of tert-butyl 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0567]
[0568] 3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (140 mg, 0.57 mmol) was dissolved in anhydrous dioxane (3 mL), and tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (183 mg, 0.68 mmol), cesium carbonate (370 mg, 1.15 mmol), Pd 2 (dba) 3(90 mg, 0.1 mmol), Xantphos (60 mg, 0.1 mmol), reacted at 110°C for 16 hours under nitrogen protection. The reaction product was concentrated and purified by silica gel column (DCM / MeOH (V / V) = 30 / 1) to obtain tert-butyl 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (80 mg).
[0569] LC-MS, M / Z(ESI):477.2[M+H] +
[0570] Step 5: Synthesis of 3-(5-methylisoxazol-3-yl)-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide hydrochloride
[0571]
[0572] Dissolve 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester (80 mg, 0.18 mmol) in tetrahydrofuran (2 mL) and add 4N hydrochloric acid dioxane (0.5 mL) to react at room temperature for 4 hours. The reaction mixture was concentrated to obtain a crude product (105.3 mg), which was directly used in the next step.
[0573] LC-MS, M / Z(ESI):377.1[M+H] +
[0574] Step 6: Synthesis of 3-(5-methylisoxazol-3-yl)-N-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide
[0575]
[0576] 3-(5-methylisoxazol-3-yl)-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide hydrochloride (105.3 mg crude product, 0.18 mmol) was dissolved in 1,2-dichloroethane (3 mL), and triethylamine (36.6 mg, 0.36 mmol) was added. The mixture was stirred at room temperature for 15 min, and then 3-oxetanone (26.1 mg, 0.36 mmol) was added. The reaction was stirred for 1 hour, and then sodium acetate borohydride (76.2 mg, 0.36 mmol) and a drop of acetic acid were added. The reaction was allowed to react overnight at room temperature. Water (5 mL) was added to the reaction and extracted three times with dichloromethane (5 mL). The organic phase was collected and concentrated, separated and purified by Pre-HPLC, and dried to give 3-(5-methylisoxazol-3-yl)-N-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (21.6 mg).
[0577] LC-MS, M / Z(ESI):433.2[M+H] +
[0578] 1 H NMR (400 MHz, CDCl 3 )δ8.38(d,J=9.8Hz,1H),8.13(dd,J=9.0,2.4Hz,2H),7.44(d,J=8.4Hz,1H),6.90(s,1H),4.74(dt,J=14. 8,6.2Hz,4H),3.79–3.69(m,1H),3.53(s,2H),3.04(t,J=6.0Hz,2H),2.72(t,J=6.0Hz,2H),2.62(s,3H).
[0579] Example 9: Preparation of target compounds I-19, I-19A and I-19B
[0580] 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0581]
[0582] (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0583]
[0584] (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0585]
[0586] The synthetic routes of target compounds I-19, I-19A and I-19B are as follows:
[0587]
[0588] Step 1: 6-(tert-butyl) 2-methyl 7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate
[0589]
[0590] At room temperature, tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (5.00 g, 18.65 mmol) and Pd(dppf)Cl 2 (1.36g, 1.86mmol) was dissolved in a mixed solution of 40mL methanol / triethylamine (V / V=8 / 1), and the reaction solution was heated at 60°C for 16 hours under the protection of carbon monoxide. LCMS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product, water (50mL) was added to the crude product, and then extracted three times with dichloromethane (30mL), the organic phases were combined, washed with saturated brine (30mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried, and the crude product was separated by column chromatography (EtOAc / PE (V / V)=1:4) to obtain 7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylic acid 6-(tert-butyl) 2-methyl ester (5.1g).
[0591] LC-MS, M / Z(ESI):293.1[M+H] +
[0592] Step 2: Synthesis of tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0593]
[0594] Under ice bath conditions, 6-(tert-butyl)-2-methyl-7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate (2g, 6.8mmol) was dissolved in a 30mL mixed solution of tetrahydrofuran / ethanol (V / V=1 / 1), and then sodium borohydride (520mg, 13.6mmol) and calcium chloride (1.52g, 13.6mmol) were added respectively. The reaction solution was reacted at room temperature for 16 hours, and LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product, which was directly separated by column chromatography (DCM / MeOH (V / V)=10:1) to obtain tert-butyl-2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (1.2g).
[0595] LC-MS, M / Z(ESI):265.2[M+H] +
[0596] Step 3: Synthesis of tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0597]
[0598] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (501 mg, 1.89 mmol), tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (500 mg, 1.89 mmol) and cesium carbonate (1.23 g, 3.78 mmol) were dissolved in acetonitrile (20 mL). The reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH=15 / 1, V / V) to obtain tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (580 mg).
[0599] LC-MS, M / Z(ESI):394.2[M+H-100] +
[0600] Step 4: Synthesis of 3-(8-methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0601]
[0602] At room temperature, tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (580 mg, 1.17 mmol) was dissolved in hydrochloric acid / dioxane (10 mL, 4 M) and then reacted at room temperature for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was concentrated to obtain 3-(8-methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridine-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (400 mg, crude product), which was directly used in the next step without purification.
[0603] LC-MS, M / Z(ESI):394.2[M+H] +
[0604] Step 5: Synthesis of 3-(6-((6-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0605]
[0606] At room temperature, 3-(8-methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (400 mg, 1.017 mmol) and 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (158 mg, 1.22 mol) were dissolved in 1,2-dichloroethane (10 mL). The reaction solution was stirred at room temperature for 30 minutes, and sodium triacetoxyborohydride (772 mg, 3.66 mmol) was added in batches. The reaction solution was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (20 mL) was added to the crude product, and then extracted three times with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (40 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by column chromatography (DCM / MeOH (V / V) = 15:1) to obtain 3-(6-((6-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (450 mg).
[0607] LC-MS, M / Z(ESI):508.2[M+H] +
[0608] Step 6: 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0609]
[0610] Under ice bath conditions, 3-(6-((6-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (450 mg, 88.7 mmol) was dissolved in methanol (10 mL). Then 3N hydrochloric acid solution (5 mL) was added dropwise and stirred at room temperature for 2 hours. LCMS detected that the reaction was complete. The reaction solution was concentrated to obtain a crude product, which was separated by high performance liquid phase separation to give 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (110 mg).
[0611] LC-MS, M / Z(ESI):468.2[M+H] +
[0612] Step 7: Synthesis of (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol and (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol
[0613] (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0614]
[0615] (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol
[0616]
[0617] 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (110 mg) was chiral separated by SFC under the following conditions: column: Chiralpak AD-3 50*4.6 mm ID, 3 μm; solvent: A=CO 2 , B = 0.05% by volume diethylamine solution in ethanol.
[0618] Peak 1 was separated and concentrated to give compound (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol or (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (74.8 mg, ee>99%, SFC retention time: 1.825 min).
[0619] LC-MS, M / Z(ESI):468.2[M+H] +
[0620] 1 H NMR (400MHz, DMSO) δ7.53(d,J=7.9Hz,1H),7.39(d,J=7.8Hz,1H),7.04(s,1H),6.74(s,1H),5.44(s,2H),4.58–4.45(m,2H),4.1 2(s,3H),3.73–3.68(m,1H),3.66(s,2H),2.93–2.87(m,2H),2.87–2.79(m,2H),2.61–2.55(m,4H),2.43(dd,J=12.7,7.0Hz,1H).
[0621] Peak 2 was separated and concentrated to give compound (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol or (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (9.2 mg, ee=80%, SFC retention time: 2.496 min).
[0622] LC-MS, M / Z(ESI):468.2[M+H] +
[0623] 1 H NMR (400MHz, DMSO) δ7.53(d,J=7.9Hz,1H),7.39(d,J=7.8Hz,1H),7.04(s,1H),6.74(s,1H),5.44(s,2H),4.58–4.45(m,2H),4.1 2(s,3H),3.73–3.68(m,1H),3.66(s,2H),2.93–2.87(m,2H),2.87–2.79(m,2H),2.61–2.55(m,4H),2.43(dd,J=12.7,7.0Hz,1H).
[0624] The SFC retention time of compound I-19A is 1.825 min, and the SFC retention time of compound I-19B is 2.496 min.
[0625] Example 10: Preparation of target compound I-21
[0626] 5-Cyclopropyl-3-(8-methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0627]
[0628] The synthetic route of the target compound I-21 is as follows:
[0629]
[0630] Step 1: Synthesis of 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0631]
[0632] 6-Chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (320 mg, 1.23 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (300 mg, 1.35 mmol) and potassium carbonate (254 mg, 1.84 mmol) were added to anhydrous acetonitrile (8 mL) in sequence, and the reaction system was reacted at room temperature for 16 hours. Water (10 mL) was added to the reaction, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was collected and concentrated to obtain a crude product. The crude product was first quickly purified by silica gel column to obtain a crude product, and then separated and purified by Pre-HPLC and dried to obtain 3-(5-methylisothiazol-3-yl)-6-((6-(oxabutane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (61.5 mg).
[0633] LC-MS, M / Z(ESI):445.2[M+H] +
[0634] 1 H NMR (400 MHz, CDCl 3 )δ7.46(d,J=7.8Hz,1H),7.39(d,J=7.8Hz,1H),7.34(s,1H),6.84(s,1H),5.57(s,2H),4.72(dt,J=21.0 ,6.4Hz,4H),3.76–3.67(m,1H),3.53(s,2H),3.08(t,J=5.8Hz,2H),2.72(t,J=6.0Hz,2H),2.59(s,3H).
[0635] Example 11: Preparation of target compound I-22
[0636] 3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile
[0637]
[0638] The synthetic route of the target compound I-22 is as follows:
[0639]
[0640] Step 1: Synthesis of 3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile
[0641]
[0642] 6-Chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (1.0 g, 3.84 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (930 mg, 4.22 mmol) and potassium carbonate (800 mg, 5.76 mmol) were added to anhydrous acetonitrile (20 mL) in sequence, and the reaction system was reacted at 50 ° C for 2 hours. After cooling to room temperature, water (20 mL) was added to the reaction, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was collected and concentrated to obtain a crude product. The crude product was first quickly purified by silica gel column to obtain a crude product, and then separated and purified by Pre-HPLC and dried to obtain 3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (100.2 mg).
[0643] LC-MS, M / Z(ESI):445.2[M+H] +
[0644] 1 H NMR (400 MHz, CDCl 3 )δ8.56(s,1H),7.51(d,J=8.0Hz,1H),7.44(d,J=8.0Hz,1H),6.87(s,1H),5.65(s,2H),4.74(dt,J=15.2, 6.4Hz, 4H), 3.76 (d, J = 6.4Hz, 1H), 3.57 (s, 2H), 3.11 (t, J = 5.8Hz, 2H), 2.76 (t, J = 6.0Hz, 2H), 2.60 (s, 3H).
[0645] Example 12: Preparation of target compound I-24
[0646] 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0647]
[0648] The synthetic route of the target compound I-24 is as follows:
[0649]
[0650] Step 1: Synthesis of methyl 6-methylpyridazine-3-carboxylate
[0651]
[0652] At room temperature, 3-chloro-6-methylpyridazine (6.0 g, 46.8 mmol) and Pd(dppf)Cl 2 (3.42g, 4.68mmol) was dissolved in a mixed solution of 60mL methanol / triethylamine (V / V=8 / 1), and the reaction solution was heated at 60°C for 16 hours under carbon monoxide protection. LCMS showed that the reaction was complete, and the reaction solution was concentrated to obtain a crude product. Water (50mL) was added to the crude product, and it was extracted three times with dichloromethane (30mL). The organic phases were combined, washed with saturated brine (30mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (EtOAc / PE (V / V)=1:4) to obtain 6-methylpyridazine-3-methylformate (4.5g).
[0653] LC-MS, M / Z(ESI):152.1[M+H] +
[0654] Step 2: Synthesis of methyl 6-(bromomethyl)pyridazine-3-carboxylate
[0655]
[0656] At room temperature, 6-methylpyridazine-3-carboxylic acid methyl ester (4.5 g, 29.6 mmol), N-bromosuccinimide (6.3 g, 35.5 mmol), azobisisobutyronitrile (0.48 g, 2.96 mmol) were dissolved in DMF (60 mL), and then reacted at 80 ° C for 45 minutes under nitrogen protection. LCMS showed that the reaction was complete. The reaction solution was added with water (60 mL), and then extracted with dichloromethane (40 mL) three times, the organic phases were combined, washed with saturated brine (30 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried, and the crude product was purified by column chromatography (PE / EtOAc (V / V) = 1 / 1) to obtain 6-(bromomethyl)pyridazine-3-carboxylic acid methyl ester (2.5 g).
[0657] LC-MS, M / Z(ESI):232.0[M+H] +
[0658] Step 3: Synthesis of 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid
[0659]
[0660] Under ice bath conditions, 2-methoxyethane-1-ol (925 mg, 12.1 mmol) was dissolved in THF (10 mL), and then sodium hydrogen (292 mg, 12.1 mmol, 60% purity) was slowly added to the reaction solution. After stirring for 10 minutes, 6-(bromomethyl)pyridazine-3-carboxylic acid methyl ester (1.4 g, 6.0 mmol) was added again, and the reaction was carried out at room temperature for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was quenched by adding 10 mL of methanol, and concentrated to obtain a crude product. The crude product was purified by column chromatography (DCM / MeOH (V / V) = 10 / 1) to obtain 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid (550 mg).
[0661] LC-MS, M / Z(ESI):213.1[M+H] +
[0662] Step 4: Synthesis of methyl 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylate
[0663]
[0664] At room temperature, 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid (550 mg, 2.6 mmol) was dissolved in methanol (10 mL), and then concentrated sulfuric acid (0.5 mL) was added dropwise, and the reaction solution was reacted at 60° C. for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was concentrated to obtain a crude product. The crude product was adjusted to pH=7-8 with a saturated sodium bicarbonate solution, and then extracted three times with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (30 mL), and the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EtOAc (V / V)=1 / 1) to obtain 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid methyl ester (230 mg).
[0665] LC-MS, M / Z(ESI):227.1[M+H] +
[0666] Step 5: Synthesis of (6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methanol
[0667]
[0668] Under ice bath conditions, methyl 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylate (230 mg, 1.07 mmol) was dissolved in a 10 mL tetrahydrofuran / ethanol (V / V=1 / 1) mixed solution, and then sodium borohydride (77.3 mg, 2.03 mmol) and calcium chloride (225.9 mg, 2.03 mmol) were added respectively. The reaction solution was reacted for 16 hours at room temperature. LCMS showed that the reaction was complete, and the reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product, which was directly separated by column chromatography (DCM / MeOH (V / V)=10:1) to obtain (6-((2-methoxyethoxy)methyl)pyridazine-3-yl)methanol (120 mg).
[0669] LC-MS, M / Z(ESI):199.1[M+H] +
[0670] Step 6: Synthesis of 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0671]
[0672] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (142 mg, 0.60 mmol), (6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methanol (120 mg, 0.60) and cesium carbonate (390 mg, 1.2 mmol) were dissolved in acetonitrile (6 mL), and then the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by high performance liquid phase to obtain 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (45.9 mg).
[0673] LC-MS, M / Z(ESI):398.2[M+H] +
[0674] 1 H NMR (400 MHz, CDCl 3)δ8.09(d,J=9.8Hz,1H),8.03(d,J=8.7Hz,1H),7.75(d,J=8.6Hz,1H),6.98(d,J=9.8Hz,1H),6.82(s,1 H),5.82(s,2H),4.92(s,2H),3.76–3.70(m,2H),3.62–3.56(m,2H),3.38(s,3H),2.58(d,J=9.2Hz,3H).
[0675] Example 13: Preparation of target compounds I-15A & I-15B
[0676] 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0677]
[0678] 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0679]
[0680] The synthetic routes of target compounds I-15A & I-15B are as follows:
[0681]
[0682] 3-(7-methoxy-6-(1-(6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisothiazol-2-yl The azole (0.22 g) was separated by SFC using the following separation method: column: CHIRALCEL OJ-3I.D. (50*4.6 mm, 3 μm); solvent: A = CO 2 , B = 0.05% by volume diethylamine in ethanol; gradient: 5%-40%.
[0683] Peak 1 was separated and concentrated to give compound 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine or 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (9.52 mg, SFC retention time: 1.53 min).
[0684] 1 H NMR (400 MHz, CDCl 3 ): δ7.39(d,1H,J 1 =8.0Hz),7.31(d,1H,J 1 =8.0Hz),7.18(s,1H),6.77(s,1H),6.23-6.18(m,1H),4.75-4.68(m,4H),4.01(s,3H),3.73-3. 66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H,J=6.4Hz)
[0685] LC-MS, M / Z(ESI):464.2[M+H] +
[0686] Peak 2 was separated and concentrated to give compound 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine or 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (17.85 mg, SFC retention time: 1.68 min).
[0687] 1 H NMR (400 MHz, CDCl 3 ): δ7.40(d,1H,J 1 =8.0Hz),7.31(d,1H,J1 =8.0Hz),7.18(s,1H),6.77(s,1H),6.23-6.18(m,1H),4.75-4.68(m,4H),4.01(s,3H),3.73-3. 66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H,J=6.4Hz)
[0688] LC-MS, M / Z(ESI):464.2[M+H] +
[0689] The SFC retention time of compound I-15A is 1.53 min, and the SFC retention time of compound I-15B is 1.68 min.
[0690] Example 14: Preparation of target compound I-10
[0691] 3-(7-(3,3-difluoroazetidin-1-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole
[0692]
[0693] The synthetic route of the target compound I-10 is as follows:
[0694]
[0695] Step 1: Synthesis of 3,6-dichloro-4-(3,3-difluoroazetidin-1-yl)pyridazine
[0696]
[0697] 3,4,6-trichloropyridazine (6.0 g, 33.14 mmol) and 3,3-difluoroazetidine hydrochloride (4.7 g, 36.46 mmol) were dissolved in DMF (50 mL), and potassium carbonate (13.7 g, 99.44 mmol) was added. After the addition, the reaction solution was reacted at 40 ° C for 3 hours. LC-MS showed that the reaction was complete. Water (100 mL) was added to the reaction solution, extracted with ethyl acetate (50 mL × 3), the organic phases were combined, washed with (30 mL) water 5 times, washed with saturated brine (30 mL) 2 times, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EA = 3 / 1, V / V) to obtain 3,6-dichloro-4-(3,3-difluoroazetidine-1-yl)pyridazine (6.1 g, yield: 77.3%).
[0698] Step 2: Synthesis of 3-chloro-4-(3,3-difluoroazetidin-1-yl)-6-hydrazine
[0699]
[0700] 3,6-Dichloro-4-(3,3-difluoroazetidine-1-yl)pyridazine (1.0 g, 4.18 mmol) was dissolved in ethanol (10 mL), and then hydrazine hydrate (2 mL) was added. The reaction solution was heated to reflux at 90°C for 9 hours. LC-MS showed that the reaction was complete. The solvent was evaporated to dryness, the organic phase was concentrated, and the residue was purified by silica chromatography (DCM / MeOH=15 / 1, V / V) to obtain 3-chloro-4-(3,3-difluoroazetidine-1-yl)-6-hydrazinepyridazine (370 mg, yield: 36.5%).
[0701] Step 3: Synthesis of 3-(6-chloro-7-(3,3-difluoroazetidine-1-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole
[0702]
[0703] At room temperature, 3-chloro-4-(3,3-difluoroazetidin-1-yl)-6-hydrazinopyridazine (370 mg, 1.5 mmol) and 5-methylisoxazole-3-carbaldehyde (200 mg, 1.73 mmol) were dissolved in ethanol (6 mL), and then the reaction solution was reacted at 90 ° C for 2 hours. LC-MS showed that the reaction was completed. The reaction solution was concentrated to obtain a crude product, DCM (10 mL) was added to the crude product, and then iodophenyl diacetic acid (569 mg, 1.73 mmol) was added to the reaction system. The reaction was allowed to react overnight at room temperature. LC-MS showed that the reaction was complete. The product was extracted with dichloromethane (10 mL × 3), and the organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EtOAc = 1 / 1, v / v) to obtain 3-(6-chloro-7-(3,3-difluoroazetidine-1-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (330 mg).
[0704] Step 4: Synthesis of 3-(7-(3,3-difluoroazetidine-1-yl)-6-((6-(oxetane-3-yl)-5,6,7-8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole
[0705]
[0706] At room temperature, 3-(6-chloro-7-(3,3-difluoroazetidine-1-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (150 mg, 0.46 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (101 mg, 0.46 mmol) and cesium carbonate (299.0 mg, 0.92 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by high performance liquid chromatography (column: Titank Prep C18 Bulk 10 μm, 30X 40mm, mobile phase: solvent A = water + 0.5% ammonia water, solvent B = acetonitrile, gradient: 52% acetonitrile) was separated to obtain 3-(7-(3,3-difluoroazetidine-1-yl)-6-((6-(oxetane-3-yl)-5,6,7-8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (70.5 mg, yield: 28.2%).
[0707] LC-MS, M / Z(ESI):510.2[M+H] +
[0708] 1 H NMR (400MHz, cdcl 3 )δ7.41(q,J=7.9Hz,2H),6.77(s,1H),6.62(s,1H),5.56(s,2H),4.73(dt,J=20.2,6.4Hz,4H),4.47(t,J =11.7Hz,4H),3.76–3.69(m,1H),3.54(s,2H),3.09(t,J=6.0Hz,2H),2.73(t,J=6.0Hz,2H),2.55(s,3H).
[0709] Example 15: Preparation of target compounds I-13 & I-13A
[0710] Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13)
[0711]
[0712] Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)
[0713]
[0714] The synthetic routes of target compounds I-13 & I-13A are as follows:
[0715]
[0716] Step 1: Synthesis of 2-(3,6-dichloropyridazin-4-yl)propan-2-ol
[0717]
[0718] 3,6-Dichloro-1,2,4,5-tetrazine (500 mg, 3.31 mmol) and 2-methyl-3-butyn-2-ol (1.39 g, 16.6 mmol) were dissolved in toluene (5 mL) and stirred at 120°C for 12 hours. After the reaction was complete, the crude product was concentrated and purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 4:1, R f 0.42) to give 2-(3,6-dichloropyridazin-4-yl)propan-2-ol (1.47 g, 42.8% yield).
[0719] LC-MS, M / Z(ESI):207.0[M+H] +
[0720] Step 2: Synthesis of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol
[0721]
[0722] Dissolve 2-(3,6-dichloropyridazin-4-yl)propan-2-ol (1.35 g, 6.52 mmol) and 5-methylisoxazole-3-carbohydrazide (920 mg, 6.52 mmol) in 1,4-dioxane (14 mL), add triethylamine hydrochloride (1.35 g, 9.78 mmol), and stir the reaction at 110 °C for 2 hours. After the reaction was complete, the crude product was filtered and concentrated to obtain a crude product, which was purified by high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25mm*5um; mobile phase: solvent A=water+0.1% ammonia water, B=acetonitrile; gradient: 8%-38%, 10min) to obtain a mixture of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (465 mg, 24.2% yield).
[0723] LC-MS, M / Z(ESI):294.0[M+H] +
[0724] Step 3: Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13) and 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)
[0725]
[0726] A mixture of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (230 mg, 783 μmol) and (6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (190 mg, 861 μmol) were dissolved in N,N-dimethylformamide (3 mL), cesium carbonate (510 mg, 1.57 mmol) was added, and the reaction was stirred at 25°C for 12 hours. After the reaction is complete, the reaction solution is directly spin-dried to obtain a crude product, which is purified by high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25mm*5um; mobile phase: solvent A=water+0.1% ammonia water, B=acetonitrile; gradient: 5%-35%, 10min), and then concentrated and dried to obtain a mixture.
[0727] The mixture was then separated and purified by supercritical fluid chromatography (chromatographic column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 um; mobile phase A: [supercritical fluid carbon dioxide]; mobile phase B: isopropanol (0.05% diethylamine), gradient elution: supercritical fluid carbon dioxide containing ethanol (0.05% diethylamine), the ratio of which was from 5% to 40%; flow rate: 3 mL / min; detector: PDA); column temperature: 35° C.; column pressure: 100 bar) to obtain 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl) methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13) (172 mg, 45.6% yield, retention time 1.704 min) and 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A) (57.5 mg, 14.1% yield, retention time 1.942 min).
[0728] 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13)
[0729] LC-MS, M / Z(ESI):478.3[M+H] +
[0730] 1 H NMR (400 MHz, CDCl 3 )δ8.20(s,1H),7.3-7.4(m,2H),6.83(s,1H),5.67(s,2H),4.75(t,J=6.4Hz,2H),4.71(t,J=6.4Hz,2H),4.47(br s,1H),3.69-3.75(m,1H),3.53(s,2H),3.09(t,2H,J=5.9Hz),2.72(t,2H,J=6.0Hz),2.58(s,3H),1.71(s,6H)
[0731] 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)
[0732] LC-MS, M / Z(ESI):478.3[M+H] +
[0733] 1 H NMR (400 MHz, CDCl 3 )δ7.5-7.5(d,J=8Hz,1H),7.4-7.5(d,J=7.6Hz,1H),6.95(s,1H),6.85(d,J=0 .6Hz,1H),5.55(s,2H),4.7-4.8(m,4H),3.93(s,1H),3.7-3.8(m,1H),3.58(br s,2H),3.12-3.15(m,2H),2.76-2.79(m,2H),2.60(s,3H),1.82(s,6H)
[0734] Example 16: Preparation of target compound I-25
[0735] 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one
[0736]
[0737] The synthetic route of the target compound I-25 is as follows:
[0738]
[0739] Step 1: Synthesis of 1-((4-methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one
[0740]
[0741] At room temperature, 6-chloro-3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazine (143 mg, 0.6 mmol), 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (200 mg, 0.6 mmol) and cesium carbonate (396.3 mg, 1.21 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was completed. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH=15 / 1, v / v) to obtain 1-((4-methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (140 mg, yield: 44%).
[0742] Step 2: Synthesis of 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one
[0743]
[0744] At room temperature, 1-((4-methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (140 mg, 0.26 mmol) was dissolved in toluene (6 mL), and trifluoromethanesulfonic acid (0.5 mL) was added. The reaction was then placed at 110° C. for 2 hours. LC-MS detected that the reaction was complete. The reaction solution was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by high performance liquid chromatography (column: Titank Prep C18 Bulk 10 μm, 30X 40 mm, mobile phase: solvent A = acetonitrile, solvent B = water + 0.5% ammonia water, gradient: 34% acetonitrile) to obtain 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (8.3 mg, yield: 7.6%)
[0745] LC-MS, M / Z(ESI):408.1[M+H] +
[0746] 1 H NMR (400MHz, DMSO) δ8.42(d,J=9.8Hz,1H),8.15(s,1H),7.73(d,J=9.4Hz,1H),7.31(d,J=9.4Hz,1H),7.24(d,J= 9.8Hz,1H),7.10(s,1H),5.58(s,2H),4.11(s,2H),3.85–3.80(m,2H),3.31(dd,J=4.6,1.6Hz,2H),2.59(s,3H).
[0747] Example 17: Preparation of target compound I-31
[0748] 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0749]
[0750] The synthetic route of the target compound I-31 is as follows:
[0751]
[0752] Step 1: Synthesis of 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0753]
[0754] 2-Chloro-5,6,7,8-tetrahydropyrido[4,3-b]pyridine hydrochloride (5.0 g, 24.6 mmol), oxetane-3-one (1.95 g, 27.08 mmol) and triethylamine (2.48 g, 24.6 mmol) were dissolved in (50 mL) 1,2-dichloroethane, stirred at room temperature for 30 minutes, and then sodium triacetylborohydride (10.3 g, 49.2 mmol) was added in batches. The reaction solution was reacted at room temperature for 16 hours, and LC-MS showed that the reaction was complete. Water (100 mL) was added to the reaction solution, and then extracted with dichloromethane (100 mL×3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (EtOAc / PE=1:1) to give 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (5.3 g, yield: 95%).
[0755] LC-MS, M / Z(ESI):225.1[M+H] +
[0756] Step 2: Synthesis of 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0757]
[0758] At room temperature, 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (5.3 g, 23.5 mmol) and Pd(dppf)Cl 2 (1.72 g, 2.35 mmol) was dissolved in methanol / triethylamine (V / V): 8 / 1 (40 mL), and the reaction solution was heated at 60°C for 16 hours under the protection of carbon monoxide. LC-MS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product, water (50 mL) was added to the crude product, and then extracted with dichloromethane (30 mL×3), the organic phases were combined, washed with saturated brine (30 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried, and the crude product was separated by column chromatography (DCM / MeOH=15:1) to obtain 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (4.5 g, yield: 77%).
[0759] LC-MS, M / Z(ESI):249.1[M+H] +
[0760] Step 3: Synthesis of dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridin-2-yl)methanol
[0761]
[0762] Under ice bath conditions, 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (300 mg, 1.2 mmol) was dissolved in deuterated methanol (5 mL), and then sodium borodeuteride (150 mg, 3.6 mmol) and calcium chloride (124 mg, 1.2 mmol) were added respectively. The reaction solution was reacted at room temperature for 4 hours, and LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product, which was directly separated by column chromatography (DCM / MeOH=10:1) to obtain dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine-2-yl)methanol (50 mg, yield: 18%).
[0763] LC-MS, M / Z(ESI):219.1[M+H] +
[0764] Step 4: Synthesis of 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0765]
[0766] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (52.6 mg, 2.24 mmol), (dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridin-2-yl)methanol (50 mg, 2.24 mmol) and cesium carbonate (140 mg, 4.48 mmol) were dissolved in acetonitrile (6 mL), and then the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was purified by high performance liquid chromatography (column: SunFire TM Prep C18OBD TM 5μm, 30X 150mm, mobile phase: solvent A = acetonitrile, solvent B = water + 0.5% formic acid, gradient: 25.2% acetonitrile) was separated to obtain 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (12 mg, yield: 13%).
[0767] LC-MS, M / Z(ESI):422.3[M+H] +
[0768] 1 H NMR (400 MHz, CDCl 3 )δ8.07(d,J=10.0Hz,1H),7.48(d,J=8.0Hz,1H),7.39(d,J=8.0Hz,1H),6.97(d,J=10.0Hz,1H),6.85(s,1H), 4.77-4.69(m,4H),3.77–3.69(m,1H),3.53(s,2H),3.11(t,J=6.0Hz,2H),2.73(t,J=6.0Hz,2H),2.59(s,3H).
[0769] Example 18: Preparation of target compound I-33
[0770] 2-(((7-(Difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0771]
[0772] The synthetic route of the target compound I-33 is as follows:
[0773]
[0774] Step 1: Synthesis of 3,6-dichloro-4-(difluoromethyl)pyridazine
[0775] 3,6-Dichloropyridazine (6.00 g, 40.3 mmol), difluoroacetic acid (4.06 g, 42.3 mmol, 2.66 mL) and sulfuric acid (5.14 g, 52.4 mmol, 2.98 mL) were dissolved in water (120 mL), and silver nitrate (821 mg, 4.83 mmol) was slowly added to the reaction solution. The reaction solution was stirred at 60°C for 0.5 hour. Ammonium persulfate (18.4 g, 80.5 mmol, 17.5 mL) was added to the reaction solution at 60°C, and the reaction solution was stirred at 70°C for 1 hour. After the reaction was completed, the reaction solution was quenched with a saturated sodium bicarbonate solution (300 mL), and then extracted with ethyl acetate (80 mL × 3). The organic phase was washed with a saturated sodium chloride solution (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain 3,6-dichloro-4-(difluoromethyl)pyridazine. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 3:1, R f 0.49) to give 3,6-dichloro-4-(difluoromethyl)pyridazine (2.80 g, 9.85 mmol, 24.5% yield, 70% purity).
[0776] LC-MS, M / Z(ESI):198.9[M+H] +
[0777] Step 2: Synthesis of 3-(6-chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole
[0778]
[0779] 5-Methylisothiazole-3-carboxylic acid hydrazide (600 mg, 4.25 mmol) and 3,6-dichloro-4-(difluoromethyl)pyridazine (1.06 g, 4.25 mmol) were dissolved in ethylene glycol monomethyl ether (4.00 mL), and then methanesulfonic acid (817 mg, 8.50 mmol, 608 μL) was added, and the reaction solution was stirred at 100 ° C for 2 hours. After the reaction was completed, the reaction solution was quenched with saturated sodium bicarbonate solution (30 mL), and then extracted with dichloromethane (20 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: dichloromethane / methanol = 1:0 / 7:1, R f The product was separated and purified by reverse phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10um; mobile phase: solvent A=water+0.1% FA, B=acetonitrile; gradient: 30%-50%, 1 min) to obtain 3-(6-chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole (600 mg, 1.60 mmol, 37.5% yield, 76% purity).
[0780] LC-MS, M / Z(ESI):285.9[M+H] +
[0781] Step 3: Synthesis of 2-(((7-(difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0782]
[0783] 3-(6-Chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole (80.0 mg, 280 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (74.0 mg, 336 μmol) were dissolved in N,N-dimethylformamide (2 mL), and then cesium carbonate (137 mg, 420 μmol) was added, and the reaction solution was stirred at 40 ° C for 12 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 2%-32%, 15min) to obtain 2-(((7-(difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (14.87 mg, 27.7μmol, 9.91% yield, 87.6% purity).
[0784] LC-MS, M / Z(ESI):470.2[M+H] +
[0785] 1 H NMR (400 MHz, DMSO-d 6 )δ8.79(s,1H),7.57(d,J=8.0Hz,1H),7.42(d,J=7.9Hz,1H),7.37-7.09(m,1H),7.22(t,J=53.5Hz,1H),7.07(d,J= 0.9Hz,1H),5.56(s,2H),4.62(t,J=6.4Hz,2H),4.52(t,J=6Hz,2H),3.63-3.65(m,1H),3.54-3.48(m,2H),2.93(br t,J=6.0Hz,2H),2.68-2.63(m,2H),2.59(s,3H)
[0786] Example 19: Preparation of target compound I-39
[0787] 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole
[0788]
[0789] The synthetic route of the target compound I-39 is as follows:
[0790]
[0791] Step 1: Synthesis of N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide
[0792]
[0793] 5-Bromo-2-hydrazinopyridine (6.0 g, 31.91 mmol) and 5-methyl-1,2,4-oxadiazole-3-carboxylic acid (4.90 g, 38.3 mmol) were dissolved in N,N-dimethylformamide (90 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.85 g, 35.7 mmol) and 1-hydroxybenzotriazole (4.31 g, 31.9 mmol) were added to the reaction solution in sequence. The reaction solution was stirred at 25 °C for 2 hours. After the reaction was completed, the reaction solution was quenched with water (100 mL) at 0°C, and then extracted with ethyl acetate (50 mL×3). The organic phase was washed with saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was purified by reverse phase purification (0.1% formic acid) to obtain N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide (3.70 g, 12.4 mmol, 38.9% yield).
[0794] LC-MS, M / Z(ESI):297.9[M+H] +
[0795] 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),8.96(s,1H),8.15(d,J=2.3Hz,1H),7.89-7.58(dd,J=2.4Hz,8.8Hz,1H),6.62(d,J=8.9Hz,1H),2.69(s,3H)
[0796] Step 2: Synthesis of 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole
[0797]
[0798] N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide (3.70 g, 12.4 mmol) and triphenylphosphine (6.51 g, 24.8 mmol) were dissolved in tetrahydrofuran (40 mL), and then triethylamine (5.02 g, 49.6 mmol, 6.91 mL) was added, and 1,1,1,2,2,2-hexachloroethane (5.88 g, 24.8 mmol, 2.81 mL) was dropped into the reaction solution at 0°C, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was poured into water (100 mL) under a nitrogen atmosphere at 0°C and extracted with ethyl acetate (50 mL×3). The organic phase was washed with a saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was slurried in ethyl acetate (30 mL) at 25°C for 15 minutes to obtain 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole (1.50 g, 5.36 mmol, 43.1% yield).
[0799] LC-MS, M / Z(ESI):279.9[M+H] +
[0800] Step 3: Synthesis of (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid
[0801]
[0802] 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole (500 mg, 1.79 mmol) and bis-oxanacol borate (680 mg, 2.68 mmol) were dissolved in 1,4-dioxane (10 mL), and then 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (131 mg, 178 μmol) and potassium acetate (526 mg, 5.36 mmol) were added, and the reaction solution was stirred at 80 ° C for 12 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 0:1, R f The reaction mixture was stirred at 400 ℃ for 1 h (0.12) to give (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid (400 mg, crude product).
[0803] LC-MS, M / Z(ESI):245.9[M+H] +
[0804] Step 4: Synthesis of 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole
[0805]
[0806] (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid (100 mg, 408 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (135 mg, 612 μmol) were dissolved in dichloromethane (4 mL), and then 4A molecular sieves (500 mg), triethylamine (124 mg, 1.22 mmol, 170 μL) and anhydrous copper acetate (74.1 mg, 408 μmol) were added. The reaction solution was stirred at 35 ° C for 24 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was first purified by column chromatography (mobile phase: dichloromethane / methanol = 30:1 / 5:1, R f 0.16) to obtain 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole, which was then separated and purified by reverse phase high performance liquid chromatography (column: Welch Xtimate C18 150*25mm*5um; mobile phase: solvent A = water + 0.1% formic acid, solvent B = acetonitrile; gradient: 1%-25%, 10min;) to obtain 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole (9.09 mg, 21.6 μmol, 5.29% yield).
[0807] LC-MS, M / Z(ESI):420.2[M+H] +
[0808] 1 H NMR (400 MHz, DMSO-d 6)δ8.68(d,J=1.8Hz,1H),8.02(d,J=9.9Hz,1H),7.61-7.49(m,2H),7.39(d,J=7.8Hz,1H),5.22( s,2H),4.62(t,J=6.4Hz,2H),4.52(t,J=6.0Hz,2H),3.64(t,J=6.3Hz,1H),3.50(s,2H),2.95(br t,J=5.8Hz,2H),2.79(s,3H),2.65(t,J=5.6Hz,2H)
[0809] Example 20: Preparation of target compound I-40
[0810] 5-(Difluoromethyl)-3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0811]
[0812] The synthetic route of the target compound I-40 is as follows:
[0813]
[0814] Step 1: Synthesis of ethyl 5-formylisoxazole-3-carboxylate
[0815]
[0816] At room temperature, ethyl 5-(hydroxymethyl)isoxazole-3-carboxylate (9.00 g, 52.6 mmol) was dissolved in dichloromethane (90 mL), the reaction solution was cooled to 0°C, and then Dess-Martin periodinane (44.6 g, 105 mmol) was added in batches. After the addition was completed, the reaction solution was stirred at 25 degrees for 2 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was separated by a chromatography column (petroleum ether: ethyl acetate 10:1 to 3:1) to obtain ethyl 5-formylisoxazole-3-carboxylate (8.10 g, 91.0% yield).
[0817] Step 2: Synthesis of ethyl 5-(difluoromethyl)isoxazole-3-carboxylate
[0818]
[0819] At room temperature, ethyl 5-formylisoxazole-3-carboxylate (8.00 g, 47.3 mmol) was dissolved in dichloromethane (80 mL), cooled to 0°C, and then diethylaminosulfur trifluoride (15.3 g, 94.6 mmol) was slowly added dropwise, and the reaction solution was stirred at 25 degrees for 2 hours. After the reaction was completed, the reaction solution was slowly poured into a saturated sodium bicarbonate solution to quench, and then dichloromethane (50 mL×3) was added for extraction. The organic phase was washed with a saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, and then filtered and concentrated to obtain ethyl 5-(difluoromethyl)isoxazole-3-carboxylate (8.00 g, crude product).
[0820] Step 3: Synthesis of 5-(difluoromethyl)isoxazole-3-carbohydrazide
[0821]
[0822] At room temperature, ethyl 5-(difluoromethyl)isoxazole-3-carboxylate (4.00 g, 20.9 mmol) was dissolved in ethanol (40 mL), and hydrazine hydrate (1.85 g, 31.4 mmol) was slowly added dropwise, and the reaction solution was stirred at 60°C for 2 hours. After the reaction, the ethanol was concentrated and dried to obtain 5-(difluoromethyl)isoxazole-3-carbohydrazide (3.60 g, crude product).
[0823] LC-MS, M / Z(ESI):178.1[M+H] +
[0824] Step 4: Synthesis of 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(difluoromethyl)isoxazole
[0825]
[0826] At room temperature, 5-(difluoromethyl)isoxazole-3-carbohydrazide (1.00 g, 5.65 mmol) and 3,6-dichloropyridazine (841 mg, 5.65 mmol) were dissolved in toluene (10 mL), and p-toluenesulfonic acid (194 mg, 1.13 mmol) was added, and the reaction solution was stirred at 110°C for 2 hours. After the reaction was completed, the reaction solution was concentrated and dried to obtain a crude product, which was purified by reverse phase (0.1% formic acid system) to obtain 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-(difluoromethyl)isoxazole (150 mg, 9.78% yield).
[0827] LC-MS, M / Z(ESI):272.0[M+H] +
[0828] 1 H NMR (400 MHz, CDCl3 )δ8.25(d,J=9.6Hz,1H),7.49(s,1H),7.31(d,J=9.6Hz,1H),6.75-7.05(t,J=53.2Hz,1H).
[0829] Step 5: Synthesis of 5-(difluoromethyl)-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole
[0830]
[0831] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(difluoromethyl)isoxazole (90.0 mg, 331 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (80.3 mg, 364 mmol) were dissolved in tetrahydrofuran (2 mL). The reaction solution was cooled to 0°C and added in batches under nitrogen protection. Sodium hydride (26.5 mg, 665 μmol, 60% purity) was added, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was poured into a 0.5M dilute hydrochloric acid solution (2 mL) for quenching, and ethyl acetate (5 mL×3) was added for extraction. The organic phase was washed with a saturated sodium chloride solution (10 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (column: Waters Xbridge 150*25mm*5um; mobile phase: solvent A = water + 0.1% ammonia water, solvent B = acetonitrile; gradient: 8%-38% B, 10min) was purified to give 5-(difluoromethyl)-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole (26.5mg, 17.1% yield).
[0832] LC-MS, M / Z(ESI):456.1[M+H] +
[0833] 1 H NMR (400 MHz, DMSO-d 6)δ8.48(d,J=10Hz,1H),7.79(t,J=1.6Hz,1H),7.54(d,J=7.6Hz,1H),7.52(t,J=52.4Hz,1H),7.42(d,J=7.6Hz,1H),7.34(d,J=10Hz 1H), 5.49 (s, 2H), 4.61 (t, J = 6.4Hz, 2H), 4.52 (t, J = 6.0Hz, 2H), 3.63 (quin, J = 6.0Hz, 1H), 3.50 (s, 2H), 2.92 (t, J = 5.6Hz, 2H), 2.64 (t, J = 6.0Hz, 2H).
[0834] Example 21: Preparation of target compound I-41
[0835] 3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole
[0836]
[0837] The synthetic route of the target compound I-41 is as follows:
[0838]
[0839] Step 1: Ethyl 5-(trifluoromethyl)isoxazole-3-carboxylate
[0840] Ethyl 2-chloro-2-(oxime)acetate (10.0 g, 65.9 mmol) and 2-bromo-3,3,3-trifluoropropene-1-ene (34.6 g, 197 mmol) were dissolved in tetrahydrofuran (100 mL), and potassium carbonate (18.2 g, 131 mmol) was added, and the reaction solution was stirred at 25 ° C for 12 hours. After the reaction was completed, 5-(trifluoromethyl)isoxazole-3-carboxylic acid ethyl ester (14.5 g, crude product) was directly filtered and used directly in the next step.
[0841] Step 2: 5-(Trifluoromethyl)isoxazole-3-carbohydrazide
[0842]
[0843] Dissolve 5-(trifluoromethyl)isoxazole-3-carboxylic acid ethyl ester (10 g, 47.82 mmol) in ethanol (120 mL), then add hydrazine hydrate (4.22 g, 71.7 mmol, 4.09 mL, 85% content) at 0°C, and stir the reaction solution at 25°C for 2 hours. After the reaction is completed, filter and concentrate directly to obtain a crude product, which is separated and purified by column chromatography (mobile phase is dichloromethane: methanol (V / V) = 10:1) to obtain 5-(trifluoromethyl)isoxazole-3-carbohydrazide (3.80 g).
[0844] LC-MS, M / Z(ESI):195.9[M+H] +
[0845] Step 3: 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole
[0846]
[0847] 3,6-Dichloropyridazine (800 mg, 5.37 mmol) and 5-(trifluoromethyl)isoxazole-3-carbohydrazide (1.47 g, 7.52 mmol) were dissolved in toluene (20 mL), and then p-toluenesulfonic acid (277 mg, 1.61 mmol) was added, and the reaction solution was stirred at 110°C for 2 hours. After the reaction was completed, the crude product was directly concentrated and separated and purified by column chromatography (mobile phase was petroleum ether: ethyl acetate (V / V) = 5:1-0:1) to obtain 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (250 mg, yield 16.1%).
[0848] LC-MS, M / Z(ESI):289.9[M+H] +
[0849] Step 4: 3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-(trifluoromethyl)isoxazole
[0850]
[0851] 3-(6-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (120 mg, 414 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (110 mg, 497 μmol) were dissolved in tetrahydrofuran (2 mL), and then sodium hydride (33.1 mg, 828 μmol, 60% content) was added at 0°C, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the mixture was cooled to 0°C, and the reaction solution was slowly added dropwise to a saturated ammonium chloride solution (10 mL) for quenching, and then extracted with ethyl acetate (10 mL × 3). The organic phase was washed with a saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25 mm*5 um; mobile phase: solvent A = water + 0.1% NH 4 HCO 3 , B = acetonitrile; gradient: 35%-65%, 9min) to give 3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (50.0 mg, yield 25.2%).
[0852] LC-MS, M / Z(ESI):474.2[M+H] +
[0853] 1 H NMR (400 MHz, DMSO-d 6 )δ8.50(d,J=9.6Hz,1H),8.20(s,1H),7.54(d,J=7.88Hz,1H),7.42(d,J=7.88Hz,1H),7.36(d,J=9.88Hz,1H),5.52(s,2H),4 .61(t,J=6.4Hz,2H),4.51(t,J=6.08Hz,2H),3.59-3.65(m,1H),3.49(s,2H),2.91(t,J=5.88Hz,2H),2.63(t,J=5.94Hz,2H).
[0854] Example 22: Preparation of target compound I-42
[0855] 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0856]
[0857] The synthetic route of the target compound I-42 is as follows:
[0858]
[0859] Step 1: Synthesis of 6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine
[0860]
[0861] At room temperature, 5-chloro-2-hydrazinopyridine (1.2 g, 8.3 mmol) and 5-methylisoxazole-3-carbaldehyde (1.02 g, 9.2 mmol) were dissolved in ethanol (20 mL), and then the reaction solution was reacted at 90° C. for 2 hours. LC-MS showed that the reaction was completed. The reaction solution was concentrated to obtain a crude product, DCM (20 mL) was added to the crude product, and then iodophenyl diacetic acid (2.97 g, 9.2 mmol) was added to the reaction system. The reaction was allowed to react overnight at room temperature. LC-MS showed that the reaction was complete, and the mixture was extracted with dichloromethane (20 mL×3). The organic phases were combined and washed with saturated brine (10 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was purified by column chromatography (PE / EtOAc (v / v) = 1 / 1) to obtain 6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine (1 g, yield: 50.6%).
[0862] LC-MS, M / Z(ESI):235.1[M+H] +
[0863] Step 2: Synthesis of 3-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine
[0864]
[0865] 6-Chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine (1.0 g, 4.2 mmol) was dissolved in 1,4-dioxane (20 mL), and then Pd(dppf)Cl 2(622 mg, 0.8 mmol), biboronic acid pinacol ester (1.3 g, 5.1 mmol) and potassium acetate (834 mg, 8.5 mmol), the reaction solution was heated to reflux at 90 ° C for 16 hours under nitrogen protection, and LC-MS showed that the reaction was complete. The solvent was evaporated, the organic phase was concentrated, and the residue was purified by silica chromatography (DCM / MeOH (V / V) = 15 / 1) to obtain 3-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine (1.3 g crude product).
[0866] LC-MS, M / Z(ESI):327.2[M+H] +
[0867] Step 3: Synthesis of (3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)boranediol
[0868]
[0869] At room temperature, 3-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine (1.3 g) was dissolved in tetrahydrofuran (20 mL), and then 1N sodium hydroxide solution (10 mL) was added. The reaction solution was reacted for 1 hour. LC-MS showed that the reaction was complete. It was used directly in the next step without treatment.
[0870] LC-MS, M / Z(ESI):245.1[M+H] +
[0871] Step 4: Synthesis of 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine-6-ol
[0872]
[0873] At room temperature, 2 mL of H 2 O 2The mixture was stirred at room temperature for 30 min. LC-MS showed that the reaction was complete. Dichloromethane (20 mL) and water (10 mL) were added to the reaction solution, and the aqueous phase was extracted. The pH of the aqueous phase was adjusted to 3-4 with 3N HCl, and then dichloromethane (30 mL) was added for extraction. The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried to give a crude product. The crude product was purified by column chromatography (DCM / MeOH (V / V) = 15 / 1) to give 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine-6-ol (250 mg).
[0874] LC-MS, M / Z(ESI):217.1[M+H] +
[0875] Step 5: Synthesis of 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazol[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0876]
[0877] At room temperature, 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine-6-ol (250 mg, 1.15 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (254 mg, 1.15 mmol), and triphenylphosphine (363 mg, 1.38 mmol) were dissolved in toluene (10 mL), stirred for 30 min under nitrogen protection, and then diisopropyl azodicarboxylate (DIAD) (350 mg, 1.73 mmol) was slowly added dropwise. The reaction was allowed to react at room temperature for 5 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product, water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3), the organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by high performance liquid chromatography (column: Titank Prep C18 Bulk 10 μm, 30X 40 mm, mobile phase: solvent A = water + 0.5% ammonia water, solvent B = acetonitrile, 52% acetonitrile) to obtain 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazol[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (8.0 mg, yield: 1.6%).
[0878] LC-MS, M / Z(ESI+):419.2[M+H]+
[0879] 1 H NMR (400 MHz, CDCl 3 )δ8.83(s,1H),7.79(d,J=10.0Hz,1H),7.42(d,J=8.0Hz,1H),7.37(d,J=8.0Hz,1H),7.29(dd,J=10.0,1.6Hz,1H),6.85(s,1H),5. 21(s,2H),4.74(dt,J=15.6,6.0Hz,4H),3.77–3.71(m,1H),3.55(s,2H),3.14(t,J=6.0Hz,2H),2.75(t,J=6.0Hz,2H),2.57(s,3H).
[0880] Example 23: Preparation of target compound I-43
[0881] 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,3-diol
[0882]
[0883] The route of target compound I-43 is as follows:
[0884]
[0885] Step 1: Synthesis of 3,6-dichloro-4-(trimethylsilyl)pyridazine
[0886]
[0887] 3,6-dichloropyridazine (12.0 g, 80.6 mmol) and trimethylsilyl chloride (10.5 g, 96.6 mmol, 12.3 mL) were dissolved in tetrahydrofuran (120 mL). After the temperature was lowered to -70 °C, a n-hexane solution (1.0 M, 177.21 mL) of 2,2,6,6-tetramethylpiperidinate lithium magnesium chloride lithium chloride was slowly added dropwise to the reaction solution. The reaction solution was stirred at -70 °C for 2 hours. After the reaction was completed, the reaction solution was quenched with a saturated ammonium chloride solution (1 L), and then extracted with ethyl acetate (300 mL × 3). The organic phase was washed with a saturated sodium chloride solution (600 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain 3,6-dichloro-4-(trimethylsilyl)pyridazine. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 30:1 / 10:1, R f0.36) to give 3,6-dichloro-4-(trimethylsilyl)pyridazine (15.0 g, 67.82 mmol, 84.2% yield).
[0888] LC-MS, M / Z(ESI):220.9[M+H] +
[0889] Step 2: Synthesis of 3-chloro-6-hydrazino-4-(trimethylsilyl)pyridazine
[0890]
[0891] 3,6-Dichloro-4-(trimethylsilyl)pyridazine (8.00 g, 36.1 mmol) was dissolved in tetrahydrofuran (80 mL), and then hydrazine hydrate (6.34 g, 126 mmol, 6.14 mL) was added, and the reaction solution was stirred at 65°C for 2 hours. After the reaction was completed, the reaction solution was concentrated at low temperature to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (column: UniSil 10-120C1870×250 mm; mobile phase: solvent A = water + 0.1% formic acid, solvent B = acetonitrile; gradient: 5%-35%, 20 min) to obtain 3-chloro-6-hydrazine-4-(trimethylsilyl)pyridazine (600 mg, 2.77 mmol, 7.65% yield).
[0892] LC-MS, M / Z(ESI):217.7[M+H] +
[0893] Step 3: Synthesis of N'-(6-chloro-5-(trimethylsilyl)pyridazine-3-yl)-4-fluorobenzohydrazide
[0894]
[0895] 3-Chloro-6-hydrazino-4-(trimethylsilyl)pyridazine (300 mg, 1.38 mmol) and triethylamine (210 mg, 2.08 mmol) were dissolved in tetrahydrofuran (6 mL), and then 4-fluorobenzoyl chloride (264 mg, 1.66 mmol) was added at 0°C, and the reaction solution was stirred at 0°C for 1 hour. After the reaction was completed, the reaction solution was poured into water (50 mL) at 0°C, and then extracted with ethyl acetate (10 mL×3). The organic phase was washed with saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, and then filtered and concentrated to obtain a brown solid crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 5:1 / 1:1, R f 0.31) to give N'-(6-chloro-5-(trimethylsilyl)pyridazin-3-yl)-4-fluorobenzohydrazide (710 mg, 2.10 mmol, 75.6% yield).
[0896] LC-MS, M / Z(ESI):339.0[M+H] +
[0897] Step 4: Synthesis of 6-chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine
[0898]
[0899] N'-(6-Chloro-5-(trimethylsilyl)pyridazin-3-yl)-4-fluorobenzohydrazide (660 mg, 1.95 mmol) and 1,2-dibromo-1,1,2,2-tetrachloro-ethane (1.27 g, 3.90 mmol) were dissolved in acetonitrile (12 mL), and then triphenylphosphine (1.28 g, 4.87 mmol) was added at 0°C, and the reaction solution was stirred at 0°C for 15 minutes. Triethylamine (1.18 g, 11.69 mmol, 1.63 mL) was added dropwise to the reaction solution at 0°C, and the reaction solution was stirred at 0°C for 3 hours. After the reaction was completed, the reaction solution was poured into water (50 mL) under a nitrogen atmosphere at 0°C, extracted with ethyl acetate (20 mL×3), and the organic phase was washed with a saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 3:1, R f 0.38) to give 6-chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine (570 mg, 1.78 mmol, 91.2% yield).
[0900] LC-MS, M / Z(ESI):321.0[M+H] +
[0901] Step 5: Synthesis of 7-bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine
[0902]
[0903] 6-Chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine (550 mg, 1.71 mmol) and 1,2-dibromo-1,1,2,2-tetrachloro-ethane (2.23 g, 8.57 mmol) were dissolved in tetrahydrofuran (11 mL), and then tetrabutylammonium difluorotriphenylstannate (1.19 g, 1.89 mmol) was added. The reaction solution was stirred at 25°C for 12 hours. After the reaction was completed, the reaction solution was poured into dichloromethane (40 mL) for dilution, and then filtered. The filtrate was concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 2:1, R f 0.33) to give 7-bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (430 mg, 1.31 mmol, 76.5% yield).
[0904] LC-MS, M / Z(ESI):328.9[M+H] +
[0905] 1 H NMR (400 MHz, DMSO-d 6 )δ9.16(s,1H),8.42-8.24(m,2H),7.53-7.47(m,2H)
[0906] Step 6: Synthesis of tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0907]
[0908] 7-Bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (210 mg, 641 μmol) and tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (203 mg, 769 μmol) were dissolved in N,N-dimethylformamide (6 mL), and then cesium carbonate (418 mg, 1.28 mmol) was added. The reaction solution was stirred at 40°C for 3 hours. After the reaction was completed, the reaction solution was poured into water (50 mL) at 0°C, and then extracted with ethyl acetate (20 mL×3). The organic phase was washed with saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 3:1 / 0:1, R fThe reaction mixture was stirred at 4 ℃ for 1 h (0.31) to give tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (250 mg, 397.46 μmol, 61.99% yield).
[0909] LC-MS, M / Z(ESI):557.0[M+H] +
[0910] Step 7: Synthesis of tert-butyl 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0911]
[0912] Tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (340 mg, 612 μmol) and cesium carbonate (399 mg, 1.22 mmol) were dissolved in 1,4-dioxane (7 mL), and then tris(dibenzylideneacetone)dipalladium (56.1 mg, 61.2 μmol), 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (52.0 mg, 122 μmol) and methanol (196 mg, 6.12 mmol, 248 μL) were added, and the reaction solution was stirred at 70° C. for 12 hours. After the reaction was completed, the reaction solution was poured into water (40 mL) at 0°C, and then extracted with ethyl acetate (20 mL×3). The organic phase was washed with a saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 5:1 / 1:1, R f 0.28) to give tert-butyl 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (116 mg, 229 μmol, 37.4% yield).
[0913] LC-MS, M / Z(ESI):507.1[M+H] +
[0914] Step 8: Synthesis of 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
[0915]
[0916] 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester (120 mg, 237 μmol) was dissolved in 1,4-dioxane (3 mL), and then a 1,4-dioxane HCl solution (2M, 3 mL) was added, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was concentrated to obtain a crude product of 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (120 mg), which was directly used in the next step.
[0917] LC-MS, M / Z(ESI):407.1[M+H] +
[0918] Step 9: Synthesis of 6-(2,2-dimethyl-1,3-dioxane-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
[0919]
[0920] 2-(((3-(4-Fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (120 mg, 270.96 μmol) and 2,2-dimethyl-1,3-dioxane-5-one (52.9 mg, 406 μmol) were dissolved in tetrahydrofuran (2.4 mL), and then sodium acetate (66.7 mg, 813 μmol) was added. After the reaction solution was stirred at 25°C for 0.5 hour, sodium acetate borohydride (115 mg, 542 μmol) was added to the reaction solution, and the reaction solution was stirred at 25°C for 12 hours. After the reaction was completed, the reaction solution was poured into water (10 mL) at 0°C, then extracted with ethyl acetate (5 mL×3), the organic phase was washed with saturated sodium chloride solution (10 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain 6-(2,2-dimethyl-1,3-dioxane-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (130 mg, crude product). It was used directly in the next step.
[0921] LC-MS, M / Z(ESI):521.2[M+H] +
[0922] Step 10: Synthesis of 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,3-diol
[0923]
[0924] 6-(2,2-Dimethyl-1,3-dioxane-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (130 mg, 249.73 μmol) was dissolved in 1,4-dioxane (1.3 mL), and then a 1,4-dioxane HCl solution (2 M, 1.30 mL) was added, and the reaction solution was stirred at 25 ° C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (column: Welch Xtimate C18 150*25mm*5μm; mobile phase: solvent A=water+0.1% formic acid, solvent B=acetonitrile; gradient: 1%-30%, 10min) to obtain 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,3-diol (45.92 mg, 94.3μmol, 37.7% yield).
[0925] LC-MS, M / Z(ESI):481.2[M+H] +
[0926] 1 H NMR (400 MHz, DMSO-d 6 )δ8.37-8.29(m,2H),7.70(s,1H),7.53(d,J=7.8Hz,1H),7.41(t,J=8.9Hz,2H),7.32(d,J=7.9Hz,1H),5.47(s,2H),4. 56-4.17(m,2H),3.98(s,3H),3.89(s,2H),3.64-3.48(m,4H),3.05-2.95(m,2H),2.92-2.81(m,2H),2.76-2.69(m,1H)
[0927] Example 24: Preparation of target compound I-44
[0928] 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0929]
[0930] The synthetic route of the target compound I-44 is as follows:
[0931]
[0932] Step 1: Synthesis of methyl 4-fluoro-5-methylisoxazole-3-carboxylate
[0933]
[0934] Methyl 5-methylisoxazole-3-carboxylate (10 g, 70.9 mmol) and a selective fluorination agent (30.1 g, 85.1 mmol) were added to 80 mL of cyclopentane sulfone in sequence, and the mixture was heated at 120 °C for 16 h. After the reaction system was cooled to room temperature, 200 mL of water was added and extracted twice with 50 mL of ethyl acetate. The organic phases were combined, dried, and concentrated. The crude product was purified by a silica gel column (PE / EA=3 / 1) to give methyl 4-fluoro-5-methylisoxazole-3-carboxylate (500 mg, yield 4.5%).
[0935] Step 2: Synthesis of 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide
[0936]
[0937] Methyl 4-fluoro-5-methylisoxazole-3-carboxylate (500 mg, 3.14 mmol) and hydrazine hydrate (800 mg, 15.7 mmol) were added to 5 mL of ethanol in sequence and reacted at 60 ° C for 2 hours. The reaction system was cooled to room temperature and concentrated, and the crude product was purified by silica gel column (DCM / MeOH=30 / 1) to give 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide (400 mg, yield 80%).
[0938] LC-MS, M / Z(ESI):160.1[M+H] +
[0939] Step 3: Synthesis of 6-chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine
[0940]
[0941] 3,6-Dichloropyridazine (374 mg, 2.51 mmol) and 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide (400 mg, 2.51 mmol) were added to 4 mL of n-butanol in sequence, and the mixture was heated to reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (PE / EA=3 / 1) to give 6-chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]triazine (350 mg, yield 54.9%).
[0942] LC-MS, M / Z(ESI):254.1[M+H] +
[0943] Step 4: Synthesis of 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0944]
[0945] 6-Chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]oxadiazine (350 mg, 1.37 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (360 mg, 1.65 mmol) and potassium carbonate (378 mg, 2.74 mmol) were added to anhydrous acetonitrile (8 mL) in sequence, and the reaction system was reacted at 50° C. for 2 hours, cooled to room temperature and reacted Water (20 mL) was added to the mixture and the mixture was extracted twice with ethyl acetate (20 mL) and concentrated. The crude product was first quickly purified by silica gel column to obtain the crude product, and then separated and purified by Pre-HPLC and dried to obtain 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (200 mg, yield 34.1%).
[0946] LC-MS, M / Z(ESI):438.2[M+H] +
[0947] 1H NMR(400MHz,cdcl3)δ8.08(d,J=9.8Hz,1H),7.39(dd,J=17.8,7.8Hz,2H),6.99(d,J=9.8Hz,1H),5.48(s,2H),4.71(dt,J= 18.6, 6.4Hz, 4H), 3.71 (p, J = 6.4Hz, 1H), 3.52 (s, 2H), 3.08 (t, J = 5.8Hz, 2H), 2.71 (t, J = 6.0Hz, 2H), 2.56 (d, J = 2.2Hz, 3H).
[0948] Example 25: Preparation of target compound I-45
[0949] 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0950]
[0951] The synthetic route of the target compound I-45 is as follows:
[0952]
[0953] Step 1: Synthesis of methyl 4-chloro-5-methylisoxazole-3-carboxylate
[0954]
[0955] Methyl 5-methylisoxazole-3-carboxylate (5 g, 35.4 mmol) and N-chlorosuccinimide (9.2 g, 70.8 mmol) were added to 60 mL of glacial acetic acid in sequence, heated at 120 °C for 16 h, and the reaction system was cooled to room temperature, 200 mL of water was added, and extracted twice with 50 mL of ethyl acetate. The organic phases were combined, adjusted to pH 7-8 with saturated sodium bicarbonate aqueous solution, and then separated again, dried and concentrated to obtain 6.0 g of crude product, which was directly used in the next step.
[0956] Step 2: Synthesis of 4-chloro-5-methylisoxazole-3-carboxylic acid hydrazide
[0957]
[0958] Methyl 4-chloro-5-methylisoxazole-3-carboxylate (2.0 g, 11.4 mmol) and hydrazine hydrate (1.2 g, 22.8 mmol) were added to 20 mL of ethanol in sequence and reacted at 60 ° C for 2 hours. The reaction system was cooled to room temperature and concentrated to obtain a crude product, which was purified by silica gel column (DCM / MeOH=30 / 1) to give 4-chloro-5-methylisoxazole-3-carboxylic acid hydrazide (1.4 g, yield 70%).
[0959] LC-MS, M / Z(ESI):176.1[M+H] +
[0960] Step 3: Synthesis of 6-chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine
[0961]
[0962] 3,6-Dichloropyridazine (760 mg, 5.11 mmol) and 4-chloro-5-methylisoxazole-3-carboxylic acid hydrazide (900 mg, 5.11 mmol) were added to 5 mL of n-butanol in sequence, and the mixture was heated under reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and filtered. The solid was washed with petroleum ether and dried to obtain 6-chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]triazine (1.0 g), which was directly used in the next step.
[0963] Step 4: Synthesis of 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine
[0964]
[0965] 6-Chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine (500 mg, 1.85 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (407 mg, 1.85 mmol) and potassium carbonate (510 mg, 3.7 mmol) were added to anhydrous acetonitrile (10 mL) in sequence, and the reaction system was reacted at 50° C. for 2 hours, cooled to room temperature and reacted Water (20 mL) was added to the mixture and the mixture was extracted twice with ethyl acetate (20 mL) and concentrated. The crude product was first quickly purified by silica gel column to obtain the crude product, and then separated and purified by Pre-HPLC and dried to obtain 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (71.2 mg, yield 8.4%).
[0966] LC-MS, M / Z(ESI):454.1[M+H] +
[0967] 1 H NMR(400MHz,cdcl3)δ8.09(d,J=9.8Hz,1H),7.44–7.31(m,2H),6.98(d,J=9.8Hz,1H),5.46(s,2H),4.71(dt,J= 17.8, 6.2Hz, 4H), 3.71 (p, J = 6.4Hz, 1H), 3.52 (s, 2H), 3.07 (t, J = 5.8Hz, 2H), 2.71 (t, J = 6.0Hz, 2H), 2.56 (s, 3H).
[0968] Example 26: The following compounds were prepared by referring to the preparation methods of the above compounds.
[0969]
[0970]
[0971]
[0972]
[0973]
[0974] In the test example of the present invention, the preparation method of the reference compound I refers to patent WO2021121294A1, and the structure is shown below:
[0975]
[0976] Biological Testing
[0977] The following test method may be used.
[0978] Test Example 1: Inverse agonist activity of compounds on α5-GABAA receptors
[0979] This test uses a HEK-293 cell line that transiently expresses GABAA (α5β3γ2) receptors. The final concentration of the test compound was prepared on the same day and dissolved in the extracellular solution. The extracellular solution is: 140mM NaCl, 5mM CsCl, 2mM CaCl 2 ·2H 2 O, 1 mM MgCl 2 6H 2 O, 5mM HEPES, 10mM D-Glucose, NaOH to adjust pH = 7.4. Intracellular solution: 130mM CsCl, 0.1mM CaCl 2 2H2O, 2mM MgCl 2 6H2O, 1.1 mM EGTA, 5 mM Na2-ATP, 10 mM HEPES, CsOH to adjust pH = 7.2. The test compound was dissolved in dimethyl sulfoxide (DMSO) and then dissolved in the extracellular fluid on the day of the test to a final concentration of 100 nM.
[0980] First, use a microelectrode puller to pull a capillary glass tube into a recording electrode, then load the electrode filled with intracellular fluid into the microelectrode holder, manipulate the microelectrode manipulator under an inverted microscope to immerse the electrode in the extracellular fluid and record the electrode resistance (Rpip). Then slowly contact the electrode to the cell surface, apply negative pressure to form a GΩ high-resistance seal. At this time, fast capacitance compensation is performed, and negative pressure is continued to be applied to break the cell membrane to form a whole-cell recording mode. Finally, slow capacitance compensation is performed and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is given. After the whole-cell seal is formed, the cell membrane voltage is clamped at -70mV and the GABA receptor current is recorded in the gap-free mode.
[0981] When detecting the reverse agonist effect of the test substance, the peak current after the EC50 concentration of GABA, the mixture of EC50 concentration of GABA and the test substance detection concentration, and the saturated concentration of GABA are quickly injected into the cell surface in sequence. After each switching of the working solution, the cells are eluted with extracellular fluid, and the next working solution is switched after the current stabilizes. The experimental data are collected by the EPC 10 amplifier (HEKA) and stored in the PatchMaster (HEKA) software. At least 2 cells are used for each concentration to repeat the test 2 times independently. All electrophysiological experiments were carried out at room temperature. During the experiment, the peak current stimulated by GABA before administration (IGABA) and the peak current after the test substance detection concentration (I Cmpd ), the peak current after the mixture of the test substance detection concentration and GABA acts (I GABA+Cmpd ) and the peak current evoked by saturating concentration of GABA (I GABA saturated ) The antagonistic effect of the test substance was calculated during the analysis, i.e. (1-(I Cmpd / I GABA )*100%), reverse agonism, i.e. (1-(I GABA+Cmpd ) / (I GABA )*100%).
[0982] Table 1. Inverse agonist activity data of compounds (100 nM) at α5-GABAA receptor
[0983]
[0984]
[0985] The experimental results show that the compound of the present invention has strong inverse agonist activity of α5-GABAA receptor.
[0986] Test Example 2: Pharmacokinetics test in rats
[0987] For the pharmacokinetic test in rats, three male SD rats weighing 180-240g were fasted overnight and 10 mg / kg was administered orally by gavage. Blood was collected before administration and at 15, 30 minutes, 1, 2, 4, 6, 8, and 24 hours after administration. The blood samples were centrifuged at 8000 rpm and 4°C for 6 minutes, and the plasma was collected and stored at -20°C. The plasma at each time point was taken, mixed with 3-5 times the amount of acetonitrile solution containing the internal standard, vortexed for 1 minute, centrifuged at 13000 rpm and 4°C for 10 minutes, the supernatant was taken, mixed with 3 times the amount of water, and an appropriate amount of the mixed solution was taken for LC-MS / MS analysis. The main pharmacokinetic parameters were analyzed by non-compartmental model using WinNonlin 7.0 software.
[0988] Table 2. Results of pharmacokinetic studies in rats
[0989]
[0990] The experimental results show that the compound of the present invention has good pharmacokinetic properties in rats.
[0991] Test Example 3: Pharmacokinetics test in mice
[0992] Mouse pharmacokinetic test, 3 male ICR mice, 20-30g, fasted overnight, oral gavage 10mg / kg. Blood was collected before administration and 5, 15, 30 minutes and 1, 2, 4, 6, 8, 24 hours after administration. Blood samples were centrifuged at 6000g / min 2-8℃ for 3 minutes, plasma was collected and stored at -20℃. Take plasma at each time point, add 10 times the amount of 50% methanol acetonitrile solution containing internal standard, mix, vortex mix for 5 minutes, centrifuge at 4000 rpm at 4℃ for 10 minutes, take the supernatant, add 1 times the amount of water and mix, take an appropriate amount of the mixture for LC-MS / MS analysis. The main pharmacokinetic parameters were analyzed by non-compartmental model using WinNonlin 7.0 software.
[0993] Table 3. Results of pharmacokinetic studies in mice
[0994]
[0995] The experimental results show that the compound of the present invention has good pharmacokinetic properties in mice and a high oral exposure.
[0996] Test Example 4: Human liver microsome stability test
[0997] The stability test of human liver microsomes was performed by incubating the compound with human liver microsomes in vitro. First, the compound to be tested was prepared into a 10mM stock solution in DMSO solvent, and then the compound was diluted to 0.15mM with acetonitrile. Human liver microsomes (Biovit) were diluted with PBS to form a microsome / buffer solution, and the solution was used to dilute the 0.15mM compound into a working solution with a compound concentration of 1.0μM and a human liver microsome concentration of 0.5mg / mL. Take a deep well plate, add 30μL of working solution to each well, and then add 30μL of preheated 2mM NADPH solution to start the reaction and incubate at 37°C. At 0, 5, 15, 30, and 60 minutes of incubation, add 300μL of methanol containing internal standard: acetonitrile = 1:1 to the corresponding wells to terminate the reaction. After the reaction was terminated with methanol containing internal standard: acetonitrile = 1:1 at the last 60 minutes, the deep-well plate was vortexed for 10 minutes (600 rpm / min) and then centrifuged for 10 minutes. After centrifugation, the supernatant was taken and purified water was added at 1:1 for LC-MS / MS detection to obtain the ratio of the peak area of the compound to the peak area of the internal standard at each time point. The peak area ratio of the compound at 5, 15, 30, and 60 minutes was compared with the peak area ratio at 0 minutes to calculate the remaining percentage of the compound at each time point, and T1 / 2 was calculated using Microsoft Excel software.
[0998] Table 4. Human liver microsome stability data
[0999]
[1000]
[1001] The stability of the compound in liver microsomes reflects the risk of its metabolic clearance in the body. The experimental results show that the compound of the present invention has good stability in humans.
[1002] Test Example 5: Inhibition test of compounds on cytochrome P450
[1003] The inhibitory potential of the compounds on the cytochrome P450 (CYP450) subtype CYP3A4 (two substrates midazolam and testosterone) was tested. First, the test compound was prepared as a 10mM stock solution in DMSO solvent, and the CYP3A4 inhibitor ketoconazole was prepared as a 10mM stock solution in DMSO solvent. The test compound was diluted to 1mM with acetonitrile, and ketoconazole was diluted to 300μM. Take 720μL of 10mM NADPH solution, add 1800μL of 12mM magnesium chloride solution, and then add 1080μL of phosphate buffer (0.1M, pH7.4) to prepare NADPH regeneration solution containing 2mM NADPH and 6mM magnesium chloride. In the reaction system, the final concentration of CYP3A4 substrate midazolam is 2μM, and the final concentration of CYP3A4 substrate testosterone is 40μM. Prepare human liver microsome solution with potassium phosphate buffer on ice at a concentration of 0.2 mg / mL. Prepare microsome working solution containing testosterone or midazolam at 2 times the final concentration with human liver microsome solution on ice. Add 100 μL of microsome working solution containing testosterone or midazolam to the test wells, and add 2 μL of 1 mM test compound or 300 μM ketoconazole to the corresponding experimental groups, and perform duplicate wells. Incubate the 96-well assay plate and NADPH solution at 37°C for 10 minutes, and add 98 μL of preheated 2 mM NADPH regeneration solution to the assay plate to start the reaction. The CYP3A4 assay plate with midazolam as the substrate was preincubated at 37°C for 3 minutes, and the CYP3A4 assay plate with testosterone as the substrate was preincubated at 37°C for 10 minutes. Add 200 μL of methanol containing internal standard: acetonitrile = 1:1 to terminate the reaction. After quenching, shake the plate on a shaker (IKA, MTS2 / 4) for 10 minutes (600 rpm / min), and then centrifuge for 10 minutes. After centrifugation, take the supernatant, add purified water at 1:1, and perform LC-MS / MS detection to obtain the ratio of the peak area of the compound to the peak area of the internal standard. The peak area ratio of the compound is compared with the peak area ratio of the control inhibitor to calculate the inhibition rate.
[1004] Table 5 Results of CYP450 enzyme inhibition test of test compounds
[1005]
[1006] The experimental results show that the compounds of the present invention have weak or no inhibitory effect on the CYP3A4 enzyme, and the risk of potential drug-drug interaction is low.
[1007] Test Example 6: Rat CFA Inflammatory Pain Model
[1008] The complete Freund's adjuvant (CFA) model is an inflammatory pain model that can be used to evaluate the relief of pain caused by inflammation. After the rats were adapted for 5-7 days, the base value of the thermal pain threshold was determined using a radiant heat light source (produced by Ugo Basile, Italy). The next day, 50 μL of complete Freund's adjuvant was injected into the left sole of the rat for modeling. On the fourth day after modeling, the animals were orally gavaged with compounds or solvents. The dose of the test sample was 20-40 mg / kg, and the dose of the control compound Naproxen was 20 mg / kg. The thermal pain threshold data of the rats were measured using a radiant heat light source (produced by Ugo Basile, Italy) 0.5-3 hours after administration. The data of each group were statistically analyzed using the SPSS16.0 software package, and the statistical method used the one-way ANOVA method to compare whether there were statistical differences between the groups, and P<0.05 was statistically different.
[1009] The experimental results are as follows Figure 1 As shown, in the CFA rat model, oral administration of the compound of the present invention significantly increased the thermal pain threshold of the animals (p<0.01), reflecting a good anti-inflammatory pain effect.
[1010] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A compound of formula IA, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug: in, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring; R1 is selected from halogen, deuterium, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 is selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; m is selected from 0, 1 or 2; Alternatively, R2 and R2 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; R4 is selected from halogen, oxo (=O), hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
2. The compound of formula IA as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, which has the structure shown below: in, X1, Ring A, Ring B, R1, R2, R3, R4, p, n, Z, L1 and L2 have the meanings as defined in claim 1, and R6 has the meaning as defined in R2; Preferably, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring; R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 and R6 are each independently selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Alternatively, R2 and R6 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; When L1 is absent, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, and R6 is hydrogen, the group for When R3 is selected from When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, R6 is methyl or methoxy, the group for When R3 is selected from R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide; Preferably, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring; R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 and R6 are each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The R2 and R6 are optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; L1 does not exist, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from R4 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.
3. The compound of formula IA as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, One or more of the following conditions are met: a), the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms; b) The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; c), the ring A is selected from a benzene ring, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine; d), the ring A is selected from a benzene ring, isoxazole or oxadiazole; e), the ring A is selected from f), wherein R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; g), wherein R1 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; h), said R1 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl; i) Selected from j) Selected from 4. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, X2 is N or CR5; R5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Preferably, R5 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; Preferably, R5 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl; X1, Ring B, R1, R2, R3, R4, R6, p, n, L1 and L2 have the meanings as defined in claim 1.
5. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, Ring B, R1, R2, R3, R4, R6, n, L1 and L2 have the meanings as defined in claim 1 R5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Preferably, R5 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; Preferably, R5 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl;.
6. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: wherein Ring B, R1, R2, R3, R4, L2 and n have the meanings as defined in claim 1; The IV-1 compound satisfies one or more of the following conditions: aa), when L2 is selected from methylene, R2 is selected from methoxy, R1 is selected from methyl, R3 is selected from bb), when L2 is selected from methylene, ring B is selected from pyridine, pyridazine, 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, 7. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, the compounds IV-2, IV-3, IV-4, IV-5, IV-6, IV-7, and IV-8 satisfy one or more of the following conditions: cc), Ring B, R1, R2, R3, R4, R6, L1, L2 and n have the meanings as defined in claim 1; Ring D is a 5-8 membered heterocycloalkyl group containing at least one O atom; dd), in the compounds IV-2 and IV-3, R2 and R6 are not hydrogen at the same time; ee), in the compounds IV-2 and IV-3, R2 and R6 are hydrogen; Selected from 8. The compound, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug according to any one of claims 1 to 7, characterized in that: The ring B is selected from a 5-10 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms; The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; and / or, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 Heterocycloalkyl groups may be saturated or unsaturated, but are not aromatic; and / or, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group is saturated; and / or, the ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridodihydropyridine, pyridomorpholine, pyridopiperidine, pyridopyrrolidine; and / or, the ring B is selected from pyridine, pyrimidine, pyridazine, pyridodihydropyridine, pyridopiperidine; And / or, the ring B is selected from And / or, the ring B is selected from and / or, Selected from and / or, Selected from 9. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, wherein the compound of formula IA is defined as described in any of the following schemes: Scenario 1: in, Compounds V-1A, V-2A, and V-3A satisfy one or more of the following conditions: ff) R1, R3, R a The definition of is as in claim 1; R2 is not tert-butyl, gg) when R3 is selected from a 4-membered heterocycloalkyl group, the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl; hh) at least one R a is deuterium (D), with a maximum of two R a is deuterium (D); ii) When R1 is methyl, R2 is methoxy, R a When all are hydrogen, R3 is selected from Scenario 2: Wherein, in the compounds of formula V-1, V-2 and V-3, R2 is not tert-butyl, R1, R2, and R3 have the definitions in claim 1; When R3 is selected from a 4-membered heterocycloalkyl group, the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl; When R1 is methyl and R2 is methoxy, R3 is selected from Solution 3: Wherein, ring D is selected from a 5-6 membered heteroolefin ring; the 5-6 membered heteroolefin ring contains 1 or 2 O; R1 and R3 have the definitions in claim 1; Solution 4: Wherein, R1 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 The cycloalkyl group is substituted with 1 to 4 deuterium (D); R2 and R3 have the meanings as defined in claim 1.
10. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, satisfies one or more of the following conditions: 1) R1 is selected from deuterium (D), halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7Cycloalkyl; when there are multiple substituents, the substituents are the same or different; 2) R1 is selected from deuterium (D), F, methyl, -CD3, cyclopropyl, and methoxy; 3) p is 0, 1, 2, 3, 4 or 5; 4) R2 and R6 are each independently selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl; The C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; 5) R2 and R6 are each independently selected from hydrogen, cyano, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl; The methyl, isopropyl, methoxy, cyclopropyl or azetidinyl group is substituted by 0, 1, 2 or 3 deuterium (D), F, Cl, Br or hydroxyl groups; 6) R2 and R6 are each independently selected from hydrogen, cyano, methyl, methoxy, difluoromethyl, trifluoromethyl, -CHF2, -O-CD3, cyclopropyl, 7) R2 and R6 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains 1, 2 or 3 heteroatoms; the heteroatoms are selected from O, N, S, and P; 8) R2 and R6 together with the carbon atom to which they are attached form 9) L1 does not exist or is selected from R a The replaced C 1-3 Alkylene; 10) L1 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, -CH(CH3)-; 11) L2 does not exist or is selected from R a The replaced C 1-3 Alkylene; 12) L2 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, -CH(CH3)-; 13) Selected from (like ), 14) R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 4-6 Heterocycloalkyl; said C 1-6 Alkyl, C 1-6 The alkoxy group is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy; the C 4-6 Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo; 15) R3 is selected from cyano, methyl, ethyl, propyl, isopropyl, oxetanyl, tetrahydropyran, piperazine, 16) R3 is selected from cyano, ethyl, 17) R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, CN, C 1-3 Alkyl, C 3-5 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; 18) The R4 is selected from deuterium (D) and oxo (═O); n is selected from 0 or 1.
11. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compounds include:
12. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compounds include:
13. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: a compound represented by Formula IA as described in claims 1-12, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug; and a pharmaceutically acceptable carrier.
14. The use of a compound of formula IA as described in claims 1 to 12, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the use of a pharmaceutical composition as described in claim 13, comprising: Regulation of α5-GABA A Receptors; and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases; And / or, preparing a method for regulating α5-GABA A Receptor, and / or prevention and / or treatment of α5-GABA A Drugs, pharmaceutical compositions or preparations for receptor-related diseases; Preferably, the α5-GABA A Diseases associated with the receptor include: pain, Alzheimer's disease, multi-infarct dementia, or stroke; Preferably, the pain is neuropathic pain, inflammatory pain or cancer pain; Preferably, the pain is selected from headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune disease, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis; Preferably, the infectious disease is selected from AIDS or postherpetic neuralgia.
